Your SlideShare is downloading. ×
4 u1.0-b978-1-4160-4224-2..50050-8..docpdf
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

4 u1.0-b978-1-4160-4224-2..50050-8..docpdf

2,044
views

Published on

Published in: Health & Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,044
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
48
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Chapter 47Thyroid Disease and Pregnancy Shahla Nader, MDThyroid disorders are among the most common endocrinopathies in thyroid growth, differentiation, and all phases of iodine metabolismyoung women of childbearing age. In large areas of the world, iodine from uptake of iodine to secretion of the two thyroid hormones. Indeficiency is the predominant cause of these disorders. In the Western the nonpregnant state, 80 to 100 μg of iodine are taken up by the glandHemisphere, these disorders are most often related to altered immu- daily. Dietary iodine is reduced to iodide, which is absorbed and clearednity. The hormonal and immunologic perturbations of pregnancy and by the kidney (80%) and thyroid (20%). Iodide is actively trapped bythe postpartum period and the dependence of the fetus on maternal the thyroid and is the rate-limiting step in hormone biosynthesis. Theiodine and thyroid hormone have profound influences on maternal iodide is converted back to iodine and organified by binding to tyrosylthyroid function and consequently on fetal well-being. Appropriate residues, which are part of the glycoprotein thyroglobulin. This processantepartum and postpartum care requires a basic knowledge of thyroid requires the enzyme thyroid peroxidase. Iodination can give rise tofunction, its alteration in pregnancy, and the more common thyroid monoiodotyrosine or diiodotyrosine, with the ratio depending on pre-diseases afflicting women in the setting of pregnancy, all of which are vailing iodine availability. Coupling of two diiodotyrosine moleculesaddressed in this chapter. The combination of thyroid disease and forms T4, and one diiodotyrosine and one monoiodotyrosine form T3.pregnancy has been the topic of several reviews,1,2 and the Endocrine Thyroglobulin is extruded into the colloid space at the center of theSociety’s guidelines for management of thyroid dysfunction during follicle, and thyroid hormone is stored as colloid.pregnancy and after delivery have recently been published.3 Hormone secretion by thyroid cells, which is also under TSH control, involves digestion of thyroglobulin and extrusion of T4 and T3 into the capillaries. Daily secretion rates approximate 90 μg of T4 and 30 μg of T3. Both circulate highly bound to protein (mainly thyroxine-Maternal-Fetal Thyroid binding globulin [TBG]), with less than 1% in free form (0.3% of T3 and 0.03% of T4). Other binding proteins include thyroxine-bindingPhysiology prealbumin and albumin. It is the free hormone that enters cells and is active.Normal Thyroid Physiology Whereas T4 is completely thyroidal in origin, only approximatelyThe thyroid gland is located in the anterior neck below the hyoid bone 20% of T3 comes directly from the thyroid. Thyroxine is metabolizedand above the sternal notch. Consisting of two lobes and connected by in most tissues (particularly in the liver and kidneys) to T3 by deiodin-the isthmus, it weighs approximately 20 to 25 g. Each lobe is divided ation. It is also metabolized to reverse T3, a metabolically inactiveinto lobules, each of which contains 20 to 40 follicles. The follicle hormone. Removal of an iodine by 5′ monodeiodination from theconsists of follicular cells, which surround a glycoprotein material outer ring of T4 results in T3, which is metabolically active. When iodinecalled colloid. is removed from the inner ring, reverse T3 is produced (Fig. 47-1) The hypothalamic-pituitary axis governs the production of thyroid Monodeiodinase type I and type II catalyze the formation of T3, whereashormone by the follicular cells. Tonic stimulation of thyrotropin- reverse T3 is catalyzed by monodeiodinase type III. Normally, approxi-releasing hormone (TRH) is required to maintain normal thyroid mately 35% of T4 is converted to T3, and 40% is converted to reversefunction, and hypothalamic injury or disruption of the stalk results in T3, but this balance is shifted in favor of the metabolically inert reversehypothyroidism. TRH, a tripeptide, is produced in the paraventricular T3 in illness, starvation, or other catabolic states.4,5 About 80% of cir-nucleus of the hypothalamus, and its local production as determined culating T3 is derived from peripheral conversion. The half-life of T4 isby mRNA is inversely related to concentrations of circulating thyroid 1 week; 5 to 6 weeks are necessary before a change in dose of T4 therapyhormones. Traversing the pituitary stalk, TRH is delivered to the pitu- is reflected in steady-state T4 values. The half-life of T3 is 1 day.itary thyrotroph by the pituitary portal circulation, and it affects Free thyroid hormone enters the cell and binds to nuclear receptorsthe production and release of thyrotropin (i.e., thyroid-stimulating and in this way signals its cellular responses.6 The affinity of T3 forhormone [TSH]). A glycoprotein, TSH is composed of α and β sub- nuclear receptors is tenfold that of T4, which helps to explain theunits, and the β subunit confers specificity. Control of TSH secretion greater biologic activity of T3. Thyroid hormone receptors belong to aoccurs by negative feedback (from circulating thyroid hormone, soma- large superfamily of nuclear-hormone receptors that include thetostatin, dopamine) or by stimulation by TRH. steroid hormone, vitamin D, and retinoic acid receptors. Thyroid hor- Thyroid gland production of thyroxine (T4) and triiodothyronine mones have diverse effects on cellular growth, development, and(T3) is regulated by TSH. On binding to its receptor, TSH induces metabolism. The major effects of thyroid hormones are genomic,
  • 2. 996 CHAPTER 47 Thyroid Disease and Pregnancy I I NH2 3′ 3′ T4 HO 5′ O 5′ CH2 CH COOH I I I I NH2 I I NH2 T3 HO O CH2 CH COOH rT3 HO O CH2 CH COOH I I FIGURE 47-1 Iodine removal. Removal of an iodine atom by 5′-monodeiodination from the outer ring of thyroxine (T4) results in the formation of metabolically active triiodothyronine (T3). Removal of an iodine atom from the inner ring results in formation of the metabolically inactive reverse triiodothyronine (rT3).stimulating transcription and translation of new proteins in a concen- state of iodine sufficiency. This does not apply when thyroid functiontration- and time-dependent manner. is compromised or iodine supply is insufficient.Maternal Thyroid Physiology Iodine Deficiency and GoiterPregnancy alters the thyroidal economy, and the hormonal changes of Increased vascularity and some glandular hyperplasia can result inpregnancy result in profound alterations in the biochemical parame- mild thyroid enlargement, but frank goiter occurs because of iodineters of thyroid function. This section reviews maternal thyroid physiol- deficiency or other thyroidal disease. Although iodine deficiency isogy, the role of maternal hormones in fetal growth and development, usually not a problem in the United States, Japan, and parts of Europe,and the development of the fetal hypothalamic-pituitary-thyroid axis. 1 to 1.5 billion people in the world are at risk, with 500 million livingThis topic was reviewed by Glinoer.7 in areas of overt iodine deficiency. The World Health Organization Three series of events occur at different times during gestation. recommends 150 μg iodine per day for adults and 200 μg for pregnantStarting in the first half of gestation and continuing until term, there women. There is increased renal iodine clearance during pregnancy,is an increase in TBG, a direct effect of increasing circulating estrogen and in the latter part of gestation, a significant amount of iodine isconcentrations. Basal levels increase twofold to threefold. This increase diverted toward the fetoplacental unit to allow the fetal thyroid tois accompanied by a trend toward lower free hormone concentrations produce its own thyroid hormones. This physiologic adaptation occurs(T4 and T3), which results in stimulation of the hypothalamic- easily with minimal hypothyroxinemia and no goiter formation inpituitary-thyroid axis. Under conditions of iodine sufficiency, the areas of iodine sufficiency. Through hypothalamic-pituitary feedback,decrease in free hormone levels is marginal (10% to 15% on average). borderline iodine intake chronically enhances thyroid stimulation.When the supply of iodine is insufficient, more pronounced effects The iodine deficiency manifests as greater hypothyroxinemia, whichoccur, and these are addressed in later sections. There is usually a trend increases TSH and thyroglobulin levels and produces thyroid hyper-toward a slight increase in TSH between the first trimester and term. trophy (Fig. 47-4). The second event takes place transiently during the first trimester In a study of otherwise healthy pregnant women living under con-and is a consequence of thyroid stimulation by increasing concentra- ditions of relative iodine restriction, thyroid volume, as assessed bytions of human chorionic gonadotropin (hCG). As hCG peaks late in ultrasonography, increased an average of 30% during pregnancy.11 Inthe first trimester, there is partial inhibition of the pituitary and tran- a selected group of these women with goitrogenesis, follow-up a yearsient lowering of TSH between 8 and 14 weeks’ gestation (Fig. 47-2). after delivery did not show a return of thyroid volumes to those foundIn about 20% of women, TSH falls below the lower limit of normal, in early pregnancy. Iodine intake should also be increased after deliv-and these women often have significantly higher hCG concentrations.8 ery, especially in breastfeeding women. Ultrasonography of neonatesThe stimulatory action of hCG has been broadly quantified; an revealed that thyroid volume was 38% larger in neonates of untreatedincrement of 10,000 IU/L is associated with a lowering of basal mothers compared with neonates of mothers treated with iodineTSH of 0.1 mU/L. In most normal pregnancies, this is of minor supplementation.12consequence.9 Other than iodine deficiency, goiter in pregnancy can be related to In the third series of events, alterations in the peripheral metabo- the following:lism of thyroid hormone occur throughout pregnancy but are moreprominent in the second half. Three enzymes deiodinate thyroid hor- Graves diseasemones: deiodinase types I, II, and III. Type I is not significantly modi- Hashimoto thyroiditisfied. Type II, which is expressed in the placenta, can maintain T3 Excessive iodine intakeproduction locally, which can be critical when maternal T4 concentra- Lymphocytic thyroiditistions are reduced. Type III is also found abundantly in the placenta, Thyroid cancerand it catalyzes the conversion of T4 to reverse T3 and conversion of T3 Lymphomato T2; this abundance may explain the low T3 and high reverse T3 con- Therapy with lithium or thionamidescentrations characteristic of fetal thyroid hormone metabolism.10 These physiologic adaptations to pregnancy, depicted in Figure In the United States, clinical studies of pregnant women and non-47-3, are attained without difficulty by the normal thyroid gland in a pregnant controls have not revealed an increase in goiter during preg-
  • 3. CHAPTER 47 Thyroid Disease and Pregnancy 997 Mother Hypothalamus TBG TRH Total T4 Pituitary TSH hCG Free T4 hCG Thyroid Thyrotropin T4, T3 Liver Fetus TBG Free hormones TBG Estrogen Total T4 Placenta Placental Deiodinases Type II - T4 to T3 Thyrotropin Type III - T4 to reverse T3 Free T4 Total T3 Free T3 FIGURE 47-3 Physiologic adaptation to pregnancy. Schematic representation of the physiologic adaptation to pregnancy shows 10 20 30 40 increased thyroxine-binding globulin (TBG) concentrations, increased Week of pregnancy levels of human chorionic gonadotropin (hCG) with its thyrotropin-like activity, and alterations in the peripheral metabolism of thyroidFIGURE 47-2 Relative changes in maternal and fetal thyroid hormones in the placenta. TRH, thyrotropin-releasing hormone; TSH,function during pregnancy. The effects of pregnancy on the thyroid-stimulating hormone, T4, thyroxine, T3, triiodothyronine.mother include a marked and early increase in hepatic production of (Adapted from Glinoer D: What happens to the normal thyroid duringthyroxine-binding globulin (TBG) and placental production of human pregnancy? Thyroid 9:631, 1999.)chorionic gonadotropin (hCG). The increased level of serum TBGincreases total serum thyroxine (T4) concentrations; hCG hasthyrotropin-like activity and stimulates maternal T4 secretion. Thetransient hCG-induced increase in the serum level of free T4 inhibits of increased renal blood flow and an increase in glomerular filtrationmaternal secretion of thyrotropin. (Reprinted by permission from rate of as much as 50%.18 If iodine excretion is greater than 100 μgBurrow GN, Fisher DA, Larsen PR: Maternal and fetal thyroid in a 24-hour period, the patient’s iodine intake is assumed to befunction. N Engl J Med 331:1072, 1994.) sufficient.19fnancy.13 Ultrasound studies from other areas replete with iodine haveconfirmed these findings.14,15 Placental-Fetal Thyroid PhysiologyIodine Metabolism in Pregnancy The thyroid gland forms as a midline outpouching of the anteriorAlthough radioactive iodine is absolutely contraindicated in preg- pharyngeal floor, migrates caudally, and reaches its final position by 7nancy, early studies using 132I showed a threefold increase in thyroidal weeks’ gestation. Lateral contributions from the fourth and fifth pha-iodine clearance in pregnant women. Another set of studies enrolling ryngeal pouches give it its bilateral shape by 8 to 9 weeks’ gestation.25 pregnant women also revealed increased radioactive iodine uptake Active trapping of iodide is detectable by week 12, and the first indica-during pregnancy compared with the nonpregnant or postpartum tion of T4 production is detectable by week 14. Hypothalamic TRH isstate.16,17 The mean renal iodine clearance almost doubles because detectable at weeks 8 to 9, and the pituitary portal circulation is func-
  • 4. 998 CHAPTER 47 Thyroid Disease and Pregnancy It appears that the first phase of maximum growth velocity of 20 developing brain structures—neuronal multiplication and organiza- tion occurring during the second trimester—corresponds to a phase during which the supply of thyroid hormones to the fetus is almost exclusively of maternal origin.20 In the second phase of maximum fetal 15 brain growth velocity, occurring from the third trimester to 2 to 3 years Thyroid hypertrophy (%) postnatally, the supply of thyroid hormone is of fetal and neonatal origin. Low maternal thyroxine concentrations in the second trimester can result in irreversible neurologic deficit in offspring. When it occurs 10 later, the damage to the fetal brain is less and is partially reversible. The need for T3 by mid-gestation for development of the human cerebral cortex was also demonstrated by Kester and associates.28 Concentra- tions of TSH, T4, T3, and reverse T3 are measurable in the amniotic 5 fluid and correlate with the fetal rather than maternal serum. Neonatal Thyroid Function Immediately after birth, there is a surge of TRH and TSH that is fol- 0 5 5 10 10 lowed by an increase in T3 (from increased T4 to T3 conversion) and a Urinary iodide (μg/dL) moderate increase in T4.10 Within a few days, the increased TSH falls to adult levels through T4 and T3 negative-feedback inhibition. Neona-FIGURE 47-4 Iodine deficiency can manifest as thyroid tal T4 and T3 concentrations return to normal adult levels within 4 tohypertrophy. The percentage of maternal thyroid hypertrophy 6 weeks.29 The transient hyperthyroxinemia can be triggered by neo-(thyroid volume > 18 mL) is plotted against the urinary iodine natal cooling and may represent an adaptation of thermogenesis toconcentration measured during the first trimester of pregnancy. extrauterine life.30,31(Reprinted by permission from Caron P, Hoff M, Bassi S, et al: Urinary In premature neonates, free T4 levels are low, TSH levels are normaliodine excretion during normal pregnancy in healthy women living in (adult), and T4 levels are related to gestational age. The clinical conse-the southwest of France: Correlation with maternal thyroid quence of this transient hypothalamic hypothyroidism is unknown,parameters. Thyroid 7:749, 1997.) but it has been associated with impaired neurologic and mental development.32-34tional by weeks 10 to 12. Until mid-gestation, fetal TSH and T4 con-centrations remain low. At 18 to 20 weeks’ gestation, the fetal thyroidgland’s iodine uptake and serum T4 concentrations begin to increase.20 Placental Transfer of Drugs AffectingConcentrations of T4 increase from 2 μg /dL at 20 weeks to 10 μg/dL Thyroid Functionat term, with increasing TBG concentrations contributing to this rise. The potential influence of the placenta on fetal thyroid and neurologicSimilarly, free fetal T4 concentrations increase from 0.1 ng/dL at 12 development is evident by the ready transfer of several agents thatweeks’ gestation to 1.5 ng/dL near term. Increases in T3 and free T3 are affect thyroid function.35,36 These agents include the following:smaller, presumably because of the availability of placental type IIIdeiodinase, which converts T4 rapidly to reverse T3. Fetal serum T3 Iodineincreases from 6 ng/dL at 12 weeks’ gestation to 45 ng/dL near term. ThionamidesFetal serum TSH increases from 4 to 8 mU/L between weeks 12 and β-Adrenergic receptor blockersterm.21,22 In summary, most fetal T4 is inactivated to reverse T3. The T3 Somatostatin(from T4 conversion or direct fetal thyroid secretion) has limited avail- Exogenous TRHability. Fetal tissues that depend on T3 for development (e.g., brain Dopamine agonists and antagonistsstructures) are supplied by local T4 to T3 conversion by means of deio- Thyroid-stimulating immunoglobulins and other antibodiesdinase type II.22 TSH does not cross the placenta. TRH and corticosteroid adminis- tered antenatally before 32 weeks’ gestation stimulates T4 release andPlacental Transfer of decreases the frequency of chronic lung disease among neonates.37Thyroid Hormones Intra-amniotic administration of T4 in the preterm setting increasesAlthough earlier studies suggested only limited T4 and T3 transfer fetal maturation, as reflected by an increase in the lecithin-to-through the placenta, later studies have shown that T4 can be found in sphingomyelin ratio and decrease in respiratory distress syndromefirst-trimester celomic fluid by 6 weeks’ gestation. Nuclear T3 receptors of the newborn.38can be identified in the brain of 10-week-old fetuses, and they increasetenfold by 16 weeks’ gestation before the fetal thyroid becomes fullyfunctional.24 These studies suggest that maternal T4 transfer occursearly in gestation and that low levels of T4 are sustained in the fetus at Pregnancy, the Immunethis time.25 Vulsma and colleagues26 reported that cord serum T4 levelsin hypothyroid neonates with glandular agenesis represented as much System, and Thyroid Diseaseas 30% of normal circulating values, a strong indication of maternal Chapter 6 offers a detailed review of pregnancy immunology. TheT4 transfer, although this has not been a uniform finding.27 fetus, with its complete set of paternal antigens, survives because of
  • 5. CHAPTER 47 Thyroid Disease and Pregnancy 999adjustments in the maternal-placental-fetal immune systems. This TABLE 47-1 FACTORS INFLUENCINGimmunologic compromise of pregnancy is orchestrated primarily by THYROXINE-BINDING GLOBULINthe placental tissues and passaged fetal cells that are able to modulatethe local and systemic maternal immune responses.39,40 Autoimmune Factors Increasing TBG Levels Factors Decreasing TBG Levelsresponses are usually reduced in pregnancy, as evidenced by ameliora- Oral contraceptives Testosteronetion of Graves disease, rheumatoid arthritis, and multiple sclerosis.41-43 Pregnancy Nephrotic syndromeAlthough there is a shift from proinflammatory TH1 cytokines to TH2 Estrogen Cirrhosiscytokines, driven perhaps by progesterone,44 it is occurring against a Hepatitis Glucocorticoidsbackground of reduced B-cell reactivity. The reduced B-cell responses Acute intermittent porphyria Severe illnessare likely orchestrated by placental sex steroids, which are powerful Inherited defect Inherited defectnegative regulators of B-cell activity. Whereas most of the immunechanges in pregnancy return to normal by 12 months after delivery, TBG, thyroxine-binding globulin.there is a marked increase after most pregnancies in many differenttypes of autoantibody secretion and an exacerbation of autoimmunedisease. In most studies, total immunoglobulin G and autoantibody early in pregnancy because of the stimulatory effects of hCG. Free T4levels rise above pre-pregnancy levels during the first 6 months after levels tend to fall through the rest of pregnancy and occasionally todelivery, suggesting continuing nonspecific immune stimulation.39 levels below those of nonpregnant women.2 Free hormone levels then fall through the rest of the pregnancy but usually not below the lower limit of normal.47 Table 47-1 outlines factors that influence TBG andLaboratory Evaluation therefore total hormone concentrations. Resistance to thyroid hormone is a rare condition encompassing aof Thyroid Function number of different defects. The pituitary and other peripheral tissues can manifest this resistance. These patients present with an increasedduring Pregnancy free T4 concentration along with an inappropriately elevated or non- suppressed TSH, and they may have goiters. Whereas patients withThyrotropin and Thyroid Hormones thyroid hormone resistance have normal α-subunit concentrations,Total T4 and total T3 are elevated because of increased TBG production patients with TSH-secreting tumors (i.e., differential diagnosis ofand reduced clearance induced by the hyperestrogenic state of preg- thyroid hormone resistance) often have elevated serum α-subunitnancy.45 The normal reference range for total T4 should be adjusted by levels.48 In a case reported by Anselmo and colleagues,49 transient thy-a factor of 1.5 for pregnant patients.2 The T3 resin uptake (i.e., indirect rotoxicosis occurred during pregnancy in a woman with resistance tolaboratory measure of available TBG binding sites) is reduced in preg- thyroid hormone caused by a mutation in the thyroid receptor β gene.nancy because increased TBG binding sites take up more of the added This thyrotoxicosis manifested clinically by hypermetabolic featuresT3, leaving less to bind to resin. The free thyroxine index, which is and paralleled the rise and peak of hCG concentrations. Symptomsa product of the total T4 and T3 resin uptake, usually falls to within ameliorated and thyroid hormone concentrations declined as preg-the normal range in pregnancy. Because free T4 can be determined, nancy progressed and hCG concentrations fell.however, third-generation TSH and free T4 assessments are the best Concern has been raised regarding unaffected fetuses of mothersways to evaluate thyroid function in pregnancy. However, automated with thyroid hormone resistance. Outcomes of pregnancies in anfree T4 assays are sensitive to alternations in binding proteins as occurs extended Azorean family with resistance to thyroid hormone werein pregnancy. Because these proteins change, they can falsely elevate or analyzed; miscarriages were found to be more common, and unaf-lower the free T4 assay result. The free T4, as measured by equilibrium fected infants born to affected mothers had lower birth weights, dem-dialysis, is not affected by these protein changes. Trimester-specific onstrating a direct toxic effect of thyroid hormone excess on thenormative data for iodine-sufficient women using specific commer- fetus.50cially available assays is not available. This topic is discussed further inthe section on Subclinical Hypothyroidism and Hypothyroxinemia. If the TSH is suppressed, suggesting overproduction of thyroid Thyrotropin Receptor Antibodieshormones, free T3 can be determined. The third-generation TSH assays Several functional types of TSH receptor antibodies are recognized.can differentiate profound from marginal suppression. Trimester- Some antibodies promote gland function (i.e., thyroid-stimulatingspecific TSH concentrations were obtained by Dashe and colleagues,46 immunoglobulins [TSIs]), some inhibit binding of TSH to its receptorwho determined these concentrations at each point during gestation (i.e., thyroid-binding inhibitory immunoglobulins [TBIIs]), and somein singleton and twin pregnancies. They constructed nomograms for enhance or inhibit thyroid growth. These antibodies can be measuredboth using regression analysis and showed significantly lower TSH by a variety of bioassays and receptor assays. For example, maternalconcentrations in the first trimester. These levels were lower in twin production of TSIs causes maternal Graves disease, is transferredpregnancies, as would be expected from the known effects of hCG. across the placenta, and can lead to neonatal Graves disease. ExcessValues were converted to multiples of the median for singleton preg- TBIIs can cause maternal and neonatal hypothyroidism.nancies at each week of gestation, and they suggested that valuesexpressed this way might facilitate comparison across laboratories andpopulations. In another study, using sensitive TSH assays, 9% of non- Antithyroid Antibodiessymptomatic first-trimester women were found to have TSH values Patients with autoimmune thyroid disease commonly develop anti-higher than 0.05 mU/L (i.e., lower limit of assay detection) but less bodies to thyroid antigens. The two most commonly determinedthan 0.4 mU/L, and another 9% had TSH values below the detection antibodies are those to thyroglobulin and to thyroid peroxidaselimit.8 Free T3 and T4 concentrations can be in the high-normal range (anti-TPO).51 Among nonpregnant women, the incidence of anti-TPO
  • 6. 1000 CHAPTER 47 Thyroid Disease and Pregnancy TABLE 47-2 EFFECTS OF DRUGS ON THYROID short term with thyroid hormones. Only two newborns had transient HORMONES AND FUNCTION hyperthyroxinemia. Although breastfeeding resulted in substantial infant amiodarone ingestion, it did not cause major changes in neonatal TEST RESULTS thyroid function. The study authors concluded that amiodarone should Inhibition of thyroid function be used only when tachyarrhythmias are unresponsive to other drugs Iodine and are life threatening and that hypothyroid neonates (and perhaps Lithium the fetus in utero) should be treated. It is prudent to monitor the infants Inhibition of T4 to T3 conversion of breastfeeding mothers who continue to use the medication.54 Glucocorticoid Ipodate Propranolol Nonthyroidal Illness and Amiodarone Propylthiouracil Thyroid Function Increased level of TSH Nonthyroidal illness has been the topic of various reviews and com- Iodine mentaries.4,5,55 Severely ill patients can manifest thyroid function test Lithium abnormalities that may correlate with functional inhibition of the Dopamine antagonists hypothalamic-pituitary-thyroid axis, impaired T4 to T3 conversion (a Decreased level of TSH constant accompaniment of nonthyroidal illness), and abnormalities Glucocorticoids in binding and clearance of thyroid hormone. Reverse T3 levels are Dopamine agonists substantially elevated because of increased T4 to reverse T3 conversion Somatostatin and impaired metabolic clearance of reverse T3. TSH concentrations Inhibition of T4 and T3 binding to binding proteins Phenytoin can be low, normal, or elevated, although seldom higher than 20 mU/ Salicylates L.55 The more severe the illness, the lower the T4 values, and this rela- Sulfonylureas tionship has been used as a prognostic indicator, because a high cor- Inhibition of gastrointestinal absorption of thyroid hormone relation has been found between a low T4 value and a fatal outcome.56 Ferrous sulfate The best test for assessing thyroid function in severely or chronically Sucralfate ill patients is the free T4 concentration. Despite the low T3 and total T4 Cholestyramine state, this situation does not represent true hypothyroidism, but rather Aluminum hydroxide an adaptation to stress, and it should not be treated. TSH, thyroid-stimulating hormone; T3, l-triiodothyronine; T4, l-thyroxine. Thyroid Dysfunction andantibodies is about 3%, with the incidence ranging from 5% to 15%among pregnant women. A substantial proportion of women with Reproductive Disorderspositive anti-TPO antibodies in early pregnancy develop postpartum Thyroid hormones are important for normal reproductive function.thyroiditis.52,53 Deficiency of thyroid hormone can result in delayed sexual develop- ment. As reviewed by Winters and Berga57 and Krassas,58 all women with infertility and menstrual disturbances should have thyroid func-Drugs and Thyroid Function tion tests, usually T4, T3, and TSH. Women with type 1 diabetes, whoTable 47-2 outlines drug effects on thyroid function and metabolism, have a relatively high incidence of hypothyroidism, should probablyabsorption of thyroid hormones, and interpretation of thyroid func- undergo screening before conception. This topic has been reviewed bytion tests. Iodine and lithium inhibit thyroid function. Propranolol and Trokoudes and coworkers.59ipodate block T4 to T3 conversion, as do glucocorticoids; however,glucocorticoids also reduce release of TSH from the pituitary, as dodopamine, dopamine agonists, and somatostatin. The antiseizure med- Hyperthyroidismication phenytoin reduces total T4 levels (up to 30%) by inhibiting the Hyperthyroidism has been linked to oligomenorrhea, hypomenorrhea,binding of thyroid hormones to binding proteins and increasing T4 amenorrhea, and infertility, although many thyrotoxic women remainclearance. Ferrous sulfate, aluminum hydroxide, and sucralfate may ovulatory. In one survey, only 21.5% of 214 thyrotoxic patients hadinhibit thyroid hormone absorption substantially—an important menstrual disturbances, compared with 50% to 60% in older series.60interaction in pregnant women who are taking both iron and thyroid Thyroxine upregulates the production of sex hormone–binding globu-hormones. lin. Elevated levels of circulating testosterone and estrogen may be Amiodarone, an iodine-rich drug, has been used in pregnancy for observed, and the clearance of testosterone is reduced. Gonadotropinmaternal or fetal tachyarrhythmias. Amiodarone and the iodine are concentrations can be tonically elevated.61,62 The substantial weight losstransferred across the placenta, exposing the fetus to the drug and iodine seen in some hyperthyroid patients can affect the hypothalamic-overload. This iodine overload can cause fetal or neonatal hypothyroid- pituitary-gonadal axis and can contribute to the infertility of severeism and goiter, because the fetus acquires the capacity to escape from hyperthyroidism.the acute Wolff-Chaikoff effect (i.e., decrease in peroxidase activity andorganification that follow iodine excess) only late in gestation. Among64 pregnancies in which amiodarone was given to the mother, 17% of Hypothyroidismprogeny developed hypothyroidism (goitrous and nongoitrous). Hypo- Hypothyroidism in fetal life does not affect the development of thethyroidism was transient, although a few of the infants were treated reproductive tract, but during childhood, it leads to sexual immaturity
  • 7. CHAPTER 47 Thyroid Disease and Pregnancy 1001and usually a delay in puberty, followed by anovulatory cycles. Almost25% of women with untreated hypothyroidism have menstrual irregu-larities. Menorrhagia occurs frequently and can reflect interference Hyperthyroidism andwith the endometrial maturational process and response to ovariansteroids; it usually responds to thyroxine treatment.63 The increased Pregnancymiscarriage rate seen in hypothyroid patients may reflect disruptedendometrial maturation. Hypothyroidism, through increased TRH, Signs and Symptomscan be associated with hyperprolactinemia, which itself can disrupt The prevalence of hyperthyroidism in pregnant women ranges fromreproductive function and menstrual cyclicity,64 leading to oligomen- 0.05% to 0.2%.78 The signs and symptoms of mild to moderate hyper-orrhea or amenorrhea. Galactorrhea can sometimes be seen in this thyroidism—heat intolerance, diaphoresis, fatigue, anxiety, emotionalsetting, as can elevated levels of luteinizing hormone, possibly through lability, tachycardia, and a wide pulse pressure—can be mimicked bydiminished dopamine secretion.65 the hypermetabolic state of normal pregnancy. However, weight loss, Women with hypothyroidism have diminished rates of metabolic tachycardia greater than 100 beats/min, and diffuse goiter are featuresclearance of androstenedione and estrone and an increase in peripheral that may suggest hyperthyroidism. Graves ophthalmopathy can bearomatization. Whereas plasma concentrations of testosterone and helpful but does not necessarily indicate active thyrotoxicosis.79 Gas-estradiol are decreased because of diminished binding activity, their trointestinal symptoms such as severe nausea and excessive vomitingunbound fractions are actually increased. Several studies have sug- can accompany thyrotoxicosis in pregnancy, as can diarrhea, myopathy,gested increased risk of miscarriage in the presence of thyroid anti- lymphadenopathy, and congestive heart failure.bodies, even in the face of a euthyroid status. Although previous studiesdid not demonstrate benefit in using T4 to treat euthyroid women withrecurrent spontaneous abortions,66-68 benefit was shown by Negro and Diagnosiscolleagues69 in a group of 115 antibody-positive women, one half of Biochemical confirmation of the hyperthyroid state can be obtainedwhom received thyroxine. Treatment decreased miscarriages and pre- through laboratory measurement of free T4, free T3, and TSH. Typi-maturity by 75% and 69%, respectively. In a thoughtful accompanying cally, elevated values of free T4 and T3 and greatly suppressed TSHeditorial, Glinoer70 stated that the statistical strength of the association values are found, but a normal free T4 level can be seen in cases of T3between miscarriages and autoimmune thyroid disease has been largely toxicosis. Other laboratory features include normochromic, normocyticconfirmed, with a threefold increase in the overall miscarriage rate. anemia; mild neutropenia; elevated levels of liver enzymes and alkalineBecause there is no reason to believe that thyroxine treatment altered phosphatase; and mild hypercalcemia. Patients may test positive for anti-autoimmunity, it was thought that the subtle deficiency in thyroid thyroid antibodies (i.e., antithyroglobulin and antithyroid peroxidase),hormone concentration or reduced ability of maternal thyroid func- but they are not specific to Graves disease. TSIs are considered to betion to adapt adequately in women with autoimmune thyroid disease the antibodies specific to Graves disease and can be measured by bioas-was the main reason for the beneficial effects of thyroid hormone says or receptor assays.80administration. Differential Diagnosis Causes of hyperthyroidism are outlined in Table 47-3. ApproximatelyRadioiodine and Gonadal Function 90% to 95% of hyperthyroid pregnant women have Graves disease, andThe prevalence of infertility, premature births, miscarriage, and genetic this can be diagnosed with certainty in a thyrotoxic pregnant womandamage in the offspring of women treated with radioactive iodine who has diffuse thyromegaly with a bruit and ophthalmopathy.for thyrotoxicosis does not seem to be increased.71,72 Although thyroid Whereas excess circulating thyroid hormones cause lid retraction andcancer doses of 131I may be associated with subsequent menstrual lid lag, proptosis and external ocular muscle palsies reflect infiltrativeirregularities, exposure to radioiodine does not appear to reduce ophthalmopathy of Graves disease. Graves disease is an autoimmunefecundity.73 In a study of 32 women who conceived after 131I treatment disease mediated by antibodies (i.e., TSIs) that activate the TSH recep-for thyroid cancer (resulting in 60 term deliveries), two childrenconceived within a year of 131I therapy had birth defects, but noanomalies were seen in the remaining 58.74 Contraception has beenrecommended for 1 year after 131I treatment. In a large study, TABLE 47-3 CAUSES OF HYPERTHYROIDISMSchlumberger and associates75 obtained data on 2113 pregnancies IN PREGNANCYconceived after exposure to 30 to 100 mCi of radioiodine given for Graves diseasethyroid cancer. The incidences of stillbirths, preterm labor, low birth Toxic adenomaweight, congenital malformations, and death during the first year of Toxic multinodular goiterlife were not significantly different between pregnancies conceived Hyperemesis gravidarumbefore or after radioiodine therapy. Miscarriages were more common Gestational trophoblastic diseasefor the women treated with 131I in the year preceding conception TSH-producing pituitary tumor(40%). Metastatic follicular cell carcinoma All women need pregnancy tests before 131I treatment. Treatment Exogenous T4 and T3late in the first trimester and in the second trimester may result De Quervain (subacute) thyroiditisin irreversible hypothyroidism in the fetus. Lactating mothers Painless lymphocytic thyroiditis Struma ovariiwho have received diagnostic or therapeutic doses of 131I should notbreastfeed their infants. These topics are reviewed by Gorman76 and TSH, thyroid-stimulating hormone; T3, l-triiodothyronine; T4,Berlin.77 l-thyroxine.
  • 8. 1002 CHAPTER 47 Thyroid Disease and Pregnancytor and stimulate the thyroid follicular cell. It affects 3% of women of directly to the control and severity of the hyperthyroidism. In a studyreproductive age.81 of hyperthyroid pregnant women, the odds ratio for low birth weight was 2.4 for those treated during pregnancy and 9.2 for those uncon- trolled during pregnancy compared with a group who was euthyroidTreatment and remained so. Similarly, prematurity was more common in theThe outcome of treatment before pregnancy is better than that of hyperthyroid group; the odds ratio was 2.8 for the controlled grouptreatment in pregnancy,82 and hyperthyroidism is therefore best treated and 16.5 for the uncontrolled group. Similar findings related to pre-before conception. If untreated or treated inadequately, women may eclampsia, with an odds ratio of 4.7 for the controlled group.84 Thishave more complications during pregnancy and delivery. Very mild was confirmed by a later study.98 In other reports, higher frequenciescases of hyperthyroidism, with adequate weight gain and appropriate of small-for-gestational-age births, congestive heart failure, andobstetric progress, may be followed carefully, but moderate or severe stillbirths have been found.82,99 It is uncertain whether untreatedcases must be treated. In a retrospective study of 60 thyrotoxic preg- Graves disease is associated with a higher frequency of congenitalnant women, preterm delivery, perinatal mortality, and maternal heart malformation.87,100failure were significantly increased among women who remained thy- Infants of mothers receiving thionamides should be evaluatedrotoxic. Thyroid hormone status at delivery correlated directly with ultrasonographically for signs of hypothyroidism, such as goiter, bra-pregnancy outcome.82 In another study by Momotani and Ito,83 hyper- dycardia, and intrauterine growth restriction. If needed, cordocentesisthyroidism at conception was associated with a 25% rate of abortion may be performed and fetal thyroid function determined; referenceand 15% rate of premature delivery, compared with 14% and 10%, ranges have been reported.101 Doses of PTU should be adjusted to keeprespectively, for euthyroid patients. Preeclampsia has also been associ- free T4 level in the upper normal range and TSH level less than 0.5 mU/ated with uncontrolled hyperthyroidism.84 L during pregnancy to avoid hypothyroidism in the fetus. PTU often can be stopped in late gestation.Thionamide Therapy PTU is not significantly concentrated in breast milk (10% of serum)Thionamide therapy has been reviewed by Cooper85 and Clark and and does not appear to affect the infant’s thyroid hormone levels inassociates.86 The thionamides inhibit the iodination of thyroglobulin any major way. Methimazole also does not appear to affect subsequentand thyroglobulin synthesis by competing with iodine for the enzyme somatic or intellectual growth in children exposed to it during lacta-peroxidase. Propylthiouracil (PTU) is more frequently prescribed in tion.87,102,103 Antithyroid medication should be taken just after breast-the United States. Carbimazole (a drug metabolized to methimazole) feeding, allowing a 3- to 4-hour interval before the woman lactatesand methimazole itself are used often in Europe and Canada. PTU (but again.not methimazole) also inhibits the conversion of T4 to T3. The goal oftherapy is to control the hyperthyroidism without causing fetal or b-Blockersneonatal hypothyroidism.87 Maternal free T4 should be maintained in β-Blockers are useful for the control of adrenergic symptoms, particu-the high-normal range. PTU is given every 8 hours at doses of 100 to larly maternal heart rate. Propranolol is commonly used in doses of 20150 mg (300 to 450 mg total daily dosage) according to thyrotoxicosis to 40 mg two or three times daily, and it inhibits T4 to T3 conversion.severity. The occasional patient may require higher doses (e.g., 600 mg Alternatively, atenolol (50 to 100 mg daily) may be used, and in anor more) because the risk of uncontrolled maternal hyperthyroidism emergency, esmolol, an ultra-short-acting cardioselective intravenousis greater than that of high-dose PTU.82 It can take 6 to 8 weeks for β-blocker, has been used successfully.104 Prolonged therapy with β-major clinical effects to manifest. After the patient is euthyroid blockers can be associated with intrauterine growth restriction, fetal(reflected by monthly free T4 and free T3 values), the dose of PTU bradycardia, and hypoglycemia.should be tapered (e.g., halved), with further reduction as the preg-nancy progresses. For many patients, PTU can be discontinued by 32 Iodidesto 36 weeks’ gestation, because remission of Graves disease during Iodides decrease circulating T4 and T3 levels by up to 50% within 10pregnancy is commonly observed, often with relapse after delivery. It days by acutely inhibiting the release of stored hormone. Their usehas been suggested that a change from stimulatory to blocking anti- is appropriate in combination with thionamides (which shouldbody activity may contribute to this remission.88 be started before the iodide) and β-blockers in patients with Maternal side effects of PTU treatment can include rash (≈5%), severe thyrotoxicosis or thyroid storm. Potassium iodide (SSKI, 5pruritus, drug-related fever, hepatitis, a lupus-like syndrome, and drops every 8 hours) is given. Sodium ipodate, a radiographicbronchospasm. An alternative thionamide can be used, although cross- contrast agent, is an alternative and has the added benefit of inhibitingsensitivity occurs in 50% of patients. Agranulocytosis, which is the conversion of T4 to T3. Its safety in pregnancy has not beenmost serious side effect, develops in only 0.1%, occurring especially in documented.older women and those receiving higher doses.89 All patients experi- Because iodides cross the placenta readily, they should be used forencing fever or unexpected sore throat on therapy should discontinue no longer than 2 weeks, or fetal goiter can result. Inadvertent use ofthe drug and have white blood cell count monitoring. Agranulocytosis iodides also follows use of Betadine cleansing solutions, iodine-con-is a contraindication to further thionamide therapy; the blood count taining bronchodilators, and the drug amiodarone. 131gradually improves over days or weeks. I thyroid ablation is contraindicated in pregnancy because the Methimazole is not used in the United States. Although the trans- radioactive iodine is concentrated in the fetal thyroid after 10 to 12placental passage is similar,90 methimazole may cause cutis aplasia, a weeks’ gestation. If a woman inadvertently receives 131I during preg-scalp deformity.91-93 Although rare, there are reports of methimazole nancy, SSKI should be given immediately, along with PTU, to blockand carbimazole embryopathy, with choanal atresia, tracheoesopha- organification and reduce radiation exposure to the fetal thyroid by ageal fistula, and facial anomalies.94-97 factor of 100 and to the fetal whole body by a factor of 10. To be of The risks of untreated hyperthyroidism need to be considered in benefit, SSKI and PTU treatment must be given within 7 to 10 days ofrelation to the risk of antithyroid medications. They appear to relate exposure.76
  • 9. CHAPTER 47 Thyroid Disease and Pregnancy 1003Surgery among these women, and it was recommended that treatment in preg-In select cases of thyrotoxicosis with severe complications or noncom- nancy was unwarranted.pliance, surgery can be performed in the pregnant patient. Two weeksof low-dose iodine therapy, such as one or two drops of SSKI daily, canreduce gland vascularity preoperatively. Surgery is best performed inthe second trimester, although it can be done in the first or third tri- Fetal and Neonatalmester.105 The risks are those of anesthesia, hypoparathyroidism, andrecurrent laryngeal nerve paralysis. Hyperthyroidism The topic of fetal and neonatal hyperthyroidism has been reviewedThyroid Storm by Zimmerman.110 Hyperthyroidism in fetuses and neonates is usuallyThyroid storm is a life-threatening exacerbation of thyrotoxicosis. Cri- produced by transplacental passage of TSIs. Although they are ateria for its diagnosis have been introduced,106 and the classic findings common component of active Graves disease, the antibodies can con-are various degrees of thermoregulatory dysfunction, central nervous tinue to be present in the maternal circulation after surgical (Fig. 47-5)system effects (e.g., agitation, delirium, coma), gastrointestinal dys- or radioactive iodine ablation or even in patients with Hashimotofunction, and cardiovascular problems manifesting as tachycardia or thyroiditis. Fetal hyperthyroidism occurs when TSIs cross the placentaheart failure. For example, a patient with a temperature of 102°F who and activate the fetal thyroid; this occurs in 1% of infants born to theseis agitated and tachycardic with a pulse rate exceeding 130 beats/min women.would be diagnosed with thyroid storm. Although rare in pregnancy, Maternal TSI levels in excess of 300% of control values areit may be seen and can be precipitated by labor and delivery, cesarean predictive of fetal hyperthyroidism99 and should be measured at 28 tosection, infection, or preeclampsia.107 Thyrotoxic cardiomyopathy may 30 weeks. The assay used should be a functional one, because TSH-also lead to heart failure in pregnancy.108 Intensive care treatment with receptor antibodies are heterogeneous and can stimulate or block thefluid and nutritional support is necessary for thyroid storm and heart TSH receptor.99,111 Neonatal syndromes have been caused by transpla-failure. A loading dose of PTU of 600 mg may be given orally or cental passage of stimulating and blocking antibodies.112through a nasogastric tube, and 200 to 300 mg of PTU is continuedevery 6 hours. An hour after the initial dose of PTU, iodine is given asfive drops of SSKI every 8 hours (or 500 to 1000 mg of intravenous Fetal Thyrotoxicosissodium iodide every 8 hours) to inhibit thyroid hormone release. If Features of fetal thyrotoxicosis include a heart rate greater than 160the patient is iodine allergic, lithium (300 mg every 6 hours) is an beats/min, growth retardation, advanced bone age, and craniosynos-alternative. Dexamethasone (2 mg every 6 hours) is also given to block tosis, all of which can be detected by ultrasound examination.113 Occa-T4 to T3 conversion. For tachycardia exceeding 120 beats/min, β- sionally, nonimmune fetal hydrops and fetal death occur with associatedblockers such as propranolol, labetalol, or esmolol may be used.1 diminished subcutaneous fat and thyroid enlargement. In utero, mostTable 47-4 summarizes the management of thyroid storm. cases are likely treated by the PTU given to the mother. This problem can arise if the mother is euthyroid but has elevated levels of TSIs.114 Cordocentesis can be used for diagnosis and for monitoring therapy.Subclinical Hyperthyroidism A combination of PTU and T4 treats the fetal hyperthyroidism while keeping the mother euthyroid.Subclinical hyperthyroidism, as defined by suppressed TSH and normalfree T4 and free T3 levels, is also seen in pregnancy. In a study by Caseyand associates,109 1.7% of women screened had subclinical hyperthy- Neonatal Thyrotoxicosisroidism, which they defined as TSH values at or below the 2.5th per- Features of thyrotoxicosis in the neonate include hyperkinesis, diar-centile for gestational age and a free T4 level of 1.75 ng/dL or less. rhea, poor weight gain, vomiting, exophthalmos, arrhythmias, cardiacPregnancy complications, morbidity, and mortality were not increased failure, hypertension (systemic and pulmonary), hepatosplenomegaly, TABLE 47-4 TREATMENT OF THYROID STORM Treatment Rationale and Cautions Dosage General care Intensive management achieved with intravenous fluid hydration and nutritional support Propylthiouracil Initial: 600 mg orally or crushed and given by NG tube Maintenance: 200-300 mg every 6 hr given orally or by NG tube Iodide Initial dose to be given 1 hr after start of PTU 5 drops of supersaturated solution of potassium iodide every 8 hr or 500-1000 mg of intravenous sodium iodide infusion every 12 hr Lithium carbonate Used if patient is allergic to iodine 300 mg every 6 hr Dexamethasone Given to block T4 to T3 conversion 2 mg every 6 hr for four doses β-Blockers Given to control tachycardia ≥ 120 beats/min IV propranolol at 1 mg/min up to several doses until blockade is (use cautiously if patient in heart failure) achieved and concurrent 60 mg of propranolol (PO or NG tube) every 6 hours or IV loading dose of 250-500 μg/kg of esmolol, followed by infusion at 50-100 μg/kg/min IV, intravenous; NG, nasogastric; PO, orally; PTU, propylthiouracil.
  • 10. 1004 CHAPTER 47 Thyroid Disease and PregnancyFIGURE 47-5 Graves disease. A, Hypothyroid 21-year-old woman who developed Graves disease at age 7 was treated by subtotalthyroidectomy. She was given maintenance therapy with thyroid hormone (0.15 mg of Synthroid) throughout pregnancy. B, Her daughter wasborn at term with severe Graves disease, goiter, and exophthalmos that persisted for 6 months. C, The child was normal at 20 months old.thrombocytopenia, and craniosynostosis. The infant should be exam- production can suppress the TSH to low or suppressed values in up toined immediately after birth. Cord blood reflects the in utero environ- 20% of normal pregnancies. Twin pregnancies can be associated withment, and by day 2 of life, the maternal antithyroid drug effects have biochemical hyperthyroidism,9 as may pregnancies complicated byreceded. Affected neonates are treated with PTU, β-blockers, iodine, trophoblastic disease. Several clinical scenarios can arise and areand glucocorticoids and digoxin, as needed. Ipodate may be preferable described in the following sections.because it blocks T4 to T3 conversion. Remission by 20 weeks iscommon, and it usually occurs by 48 weeks; occasionally, there ispersistent disease when there is a strong family history of Graves Gestational Transient Thyrotoxicosisdisease. Gestational transient thyrotoxicosis (GTT) occurs in the first trimester Other mechanisms of fetal and neonatal hyperthyroidism include in women without a personal or family history of autoimmune disease.activating mutations of the stimulatory G protein in McCune-Albright It results directly from hCG stimulation of the thyroid. Glinoer andsyndrome and activating mutations of the TSH receptor.115,116 colleagues8 found an overall prevalence of GTT in 2.4% in a prospec- tive cohort study between 8 and 14 weeks’ gestation. Symptoms com- patible with thyrotoxicosis were often present, and elevated free T4 concentrations were found. The GTT was transient, paralleled theHyperthyroidism Related decline in hCG, and usually did not require treatment. The thyroid gland was not enlarged. Occasionally, β-blockers were used. GTT wasto Human Chorionic not associated with a less favorable outcome of pregnancy.GonadotropinWhen hyperthyroidism is diagnosed during the first trimester, the Hyperemesis Gravidarumphysician has a challenging differential diagnosis, usually that of Graves Hyperemesis gravidarum is a serious pregnancy complication associ-disease versus hCG-mediated hyperthyroidism. The hCG has TSH-like ated with weight loss and severe dehydration, often necessitating hos-stimulatory activity, which can result in overproduction of thyroid pitalization.119 Biochemical hyperthyroidism is found in most womenhormone when the concentrations are high or when there is a change with this condition.120,121 Whereas Goodwin and colleagues120,121 foundin its molecular structure. Molecular variants of hCG with increased that the severity of disease varied directly with the hCG concentration,thyrotropic potency include basic molecules with reduced sialic acid Wilson and associates122 did not find such a correlation. As in thecontent, truncated molecules lacking the C-terminal tail, or molecules case of GTT, certain hCG fractions may be more important than totalin which the 47-48 peptide bond in the β-subunit loop is nicked.117 hCG as thyroid stimulators.123 The duration of the hyperthyroidismThis relationship is further complicated by differences in clearance varies widely from 1 to 10 weeks but is usually self-limited. Vomitingrates of different hCG glycoforms.118 In vivo thyrotropic activity is and normalization of T4 levels occur by 20 weeks, though TSH mayregulated by the glycoforms and the plasma half-life. remain suppressed a little longer. Treatment is usually supportive, with The hCG concentrations peak at 6 to 12 weeks and then decline to correction of dehydration, antiemetics, and occasionally, parenterala plateau after 18 to 20 weeks. The stimulation of thyroid hormone nutrition. The vomiting may not be controlled by normalization of
  • 11. CHAPTER 47 Thyroid Disease and Pregnancy 1005 Clinical Disorders Defective ontogenesis Iodine Fetus Normal Normal (congenital deficiency hypothyroidism) Iodine Hypothy- Mother Normal Normal deficiency roxinemia Thyroxinemia in the fetus Contribution arising from maternal hormone transfer Conception Mid- gestation Term FIGURE 47-6 Thyroid function disorders. Schematic representation of the three sets of clinical conditions that can affect thyroid function in the mother alone, in the fetus alone, or in the fetomaternal unit shows the relative contributions of impaired maternal or fetal thyroid function that may eventually lead to alterations in fetal thyroxinemia. (Reprinted by permission from Glinoer D, Delange F: The potential repercussions of maternal, fetal and neonatal hypothyroxinemia on the progeny. Thyroid 10:871, 2000.)thyroid hormones. In patients who require treatment, PTU therapy adenoma. If either of these entities is diagnosed during pregnancy, thecan be attempted if tolerated; methimazole suppositories can also be correct treatment is control of hyperthyroidism with antithyroid drugsused. until definitive treatment (i.e., surgery or radioactive iodine) can be administered after delivery. Even less common causes of hyperthyroidism in pregnancy areGestational Trophoblastic Disease listed in Table 47-3. They include TSH-producing pituitary tumors,Both hydatidiform mole and choriocarcinoma can be associated with metastatic follicular thyroid cancer, viral (de Quervain) thyroiditis, andhCG levels that are greater than 1000 times normal and thus can cause struma ovarii, which is an ovarian dermoid tumor in which more thanhyperthyroidism (biochemically seen in approximately 50% of such 50% of the neoplasm consists of thyroid tissue.women). The thyroid is usually not enlarged. Treatment of the hyda-tidiform mole or choriocarcinoma restores thyroid function to normal.Treatment with antithyroid drugs and β-blockers is frequently neces-sary, however, before surgical treatment of the mole.124 Iodine Deficiency, Hypothyroidism,Recurrent Gestational Hyperthyroidism and PregnancyCases of recurrent gestational hyperthyroidism have been described.125,126In the case described by Rodien and colleages,126 the hyperthyroidism A schematic representation of the clinical conditions that can affectwas caused by a mutant TSH receptor that was hypersensitive to thyroid function in the mother, fetus, or fetomaternal unit is providedhCG. in Figure 47-6. Although iodine deficiency is rare in the United States, it is a common cause of maternal, fetal, and neonatal hypothyroidism in the world, where 1 to 1.5 billion are at risk and 500 million live inOther Causes of Hyperthyroidism areas of overt iodine deficiency. Worldwide, it is the most commonMuch less common causes of hyperthyroidism include thyrotoxicosis cause of mental retardation.factitia (i.e., ingestion of exogenous hormone surreptitiously); in such In the past few decades, the physiology of maternal and fetal iodinecases, serum thyroglobulin, which is produced by the thyroid, is sup- metabolism, thyroid hormone metabolism, and fetal brain develop-pressed.127 Women with large nodular goiters may have hyperthyroid- ment and the pathophysiology of iodine deficiency have been unrav-ism from autonomously functioning nodules within such goiters. eled. These findings have revealed a fascinating aspect of pregnancyAlternatively, women can have hyperthyroidism from a single toxic physiology. Iodine deficiency and hypothyroidism in pregnancy con-
  • 12. 1006 CHAPTER 47 Thyroid Disease and Pregnancytinue to be a worldwide problem worthy of resolution. This topic also of iodine deficiency, it appeared to be responsible for an IQ loss of 13.5has been a subject of numerous reviews.128-131 Even in the United States, points.135 Even borderline iodine deficiency, as seen in Europe, can beiodine intake has declined, and 15% of women of childbearing age and accompanied by impaired school achievements by apparently normal7% of pregnant women were found to have urinary iodine excretions children, as reviewed by Glinoer.129below 50 μg/L, indicative of moderate iodine deficiency.132 Actions taken to eradicate iodine deficiency have prevented the Pregnancy is an environmental trigger for the thyroid machinery, occurrence of mental retardation in millions of infants throughoutinducing changes in people who live in geographic areas that have the world. In a study by Xue-Yi and coauthors136 of a severely iodine-iodine deficiency. Four biochemical markers are useful for following deficient area of the Xinjiang region of China, iodine was administeredthe changes induced: to pregnant women. The prevalence of moderate or severe neurologic abnormalities among 120 infants whose mothers received iodine in the1. Relative hypothyroxinemia first or second trimester was 2%, compared with 9% (of 952 infants)2. Preferential T3 secretion as reflected by an elevated T3/T4 molar when the mothers received iodine in the third trimester (P = .008). ratio Although treatment in the third trimester did not improve neurologic3. Increased TSH after the first trimester, progressing until term status, head growth and developmental quotients improved slightly.4. Supranormal thyroglobulin concentrations correlating with gesta- The importance of thyroid hormone to fetal and neonatal well- tional goitrogenesis being and development was highlighted by a remarkable case of an infant born to a mother with strongly positive TSH receptor-blocking Goitrogenesis also occurs in the fetus, indicating the exquisite sen- antibodies. The mother was profoundly hypothyroid when tested aftersitivity of the fetal thyroid gland to the consequences of maternal delivery. The infant was delivered by cesarean section because of bra-iodine deficiency. This process can start during the earliest stages of dycardia. She was also profoundly hypothyroid and required intuba-fetal thyroid development. It occurs against a background of low initial tion. Her brain size was reduced, and her auditory brainstem responsematernal intrathyroidal iodine stores, the increased need for iodine was absent at age 2 months. The audiogram at age 4 years revealedafter pregnancy occurs, and the insufficiency of iodine intake through- sensorineural deafness. At age 6 years, motor development was theout the gestation. same as at age 4 months. She required T4 for 8 months until the anti- It appears that maternal thyroxine, traversing the placenta during body effect had worn off. Her physical growth was normal. Thethe first trimester and subsequently, is necessary for fetal brain devel- outcome of severe thyroid hormone deficiency in utero was fetal dis-opment. Even before fetal thyroid hormone synthesis, T3 receptors are tress, permanent auditory deficit, brain atrophy, and severely impairedfound in fetal brain tissues, and local conversion of T4 to T3 can occur. neuromotor development despite adequate neonatal treatment.137Iodine deficiency perpetuates the process, because the fetus is less The Institute of Medicine of the National Academy of Sciences hasable to synthesize thyroid hormones even when the fetal thyroid has set the iodine requirement as 110 μg for infants 0 to 6 months, 130 μgdeveloped. for infants 7 to 12 months, 90 μg for children 1 to 8 years, 120 μg for In severe iodine deficiency (intake of 20 to 25 μg/day), a condition those 9 to 13 years, and 150 μg for those older than 13 years. The rec-known as endemic cretinism occurs, with a prevalence up to 15% in ommended intake for pregnancy and lactation is 200 μg/day. Evenseverely affected populations. These infants are characterized by severe higher intakes (300 to 400 μg/day) have been suggested.138mental retardation with a neurologic picture including deaf-mutism,squint, and pyramidal and extrapyramidal syndromes. There are fewclinical signs of thyroid failure. A remarkable exception to this picturehas emerged from Africa, where the cretins have less mental retarda- Hypothyroidismtion and less in the way of neurologic deficits. The clinical picture isthat of severe thyroid failure with dwarfism, delayed sexual maturation, Signs and Symptomsand myxedema. Thyroid function is grossly impaired. Hypothyroidism occurs with a frequency of 1 case in 1600 to 2000 The consensus is that the neurologic picture of endemic cretinism deliveries.67 Population screening studies have revealed a higher inci-results from insults to the developing brain, occurring perhaps during dence. In a study in the United States, serum TSH levels were deter-the first trimester (in the case of deafness) and mostly during the mined in 2000 women between gestational weeks 15 to 18; 49 (2.5%)second trimester, with the cerebellar abnormalities resulting from had TSH levels greater than or equal to 6 mU/L, and positive thyroidpostnatal insult. This is supported by the observation that the full antibodies were found in 58% of these 49 women, compared with 11%picture can be prevented only when the iodine deficiency is corrected of control euthyroid pregnant women.139 In a Japanese study, onlybefore the second trimester and, optimally, even before conception.133 0.29% had an elevated TSH level.140 In another U.S. study, 1 infant inIn Africa, iodine deficiency is complicated by selenium deficiency. The 1629 deliveries had hypothyroidism.141deficiency of selenium leads to accumulation of peroxide, and excess Women with hypothyroidism have higher pregnancy complicationperoxide leads to destruction of thyroid cells and hypothyroidism.134 rates. As well as miscarriages, complications include preeclampsia, pla-Selenium deficiency also induces monodeiodinase I (a selenoenzyme) cental abruption, low birth weight, prematurity, and stillbirths.142deficiency, resulting in reduced T4 to T3 conversion and increased avail- These outcomes can be improved with early therapy. Gestationalability of maternal T4 for the fetal brain. This protective mechanism hypertension is also more common.141may prevent the development of neurologic cretinism, and the com- The symptoms of hypothyroidism are insidious and can be maskedbined iodine-selenium deficiency prevalent in Africa may help explain by the hypermetabolic state of pregnancy. Symptoms can includethe predominance of the myxedematous type observed there. modest weight gain, decrease in exercise capacity, lethargy, and intoler- The neurologic abnormalities and mental retardation depend ulti- ance to cold. In moderately symptomatic patients, constipation,mately on the timing and severity of the brain insult. Endemic cretin- hoarseness, hair loss, brittle nails, and dry skin also can occur. Physicalism constitutes only the extreme expression of the spectrum of physical signs may include a goiter, a thyroidectomy scar, and delay in theand intellectual abnormalities. In a meta-analysis of 18 studies in areas relaxation phase of deep tendon reflexes.
  • 13. CHAPTER 47 Thyroid Disease and Pregnancy 1007 Laboratory confirmation is obtained from an elevated TSH level, the third trimester in about one third of patients.2 In a study of 12with or without suppressed free T4. Test results for thyroid autoanti- pregnant women with hypothyroidism, 9 required a higher T4 dose,bodies (antithyroglobulin and antithyroid peroxidase) may be positive. with a mean dose increase of 45%.146 In a review of 77 pregnancies inOther laboratory abnormalities can include elevated levels of creatine 65 hypothyroid women, serum TSH levels became abnormal in 70%phosphokinase, cholesterol, and carotene and liver function abnor- of women with prior 131I ablation therapy and in 47% of women withmalities. Patients may have macrocytic or normochromic, normocytic chronic thyroiditis. When data from other studies were pooled, overall,anemia. Hypothyroidism may occur more frequently in pregnant TSH levels increased above normal in 45% with a mean daily thyroxinewomen with type 1 diabetes, and T4 replacement therapy can increase dose of 146 μg.147,148 It was estimated that the increment in dose couldinsulin requirements.143 be predicted according to the TSH value at the first evaluation. The TSH concentration should be determined again 4 to 6 weeks after dose adjustment.Differential Diagnosis The causes of increased T4 requirements include a real increasedHashimoto thyroiditis, also known as chronic lymphocytic thyroiditis, demand for T4 in pregnancy149 in patients whose thyroid reserve isan autoimmune disease, is the most common cause of hypothyroidism compromised and, in some cases, iron therapy. Ferrous sulfate inter-and can occur in 8% to 10% of women of reproductive age. It is char- feres with T4 absorption and should be taken at a different time of dayacterized by the presence of antithyroid antibodies, and the patient from thyroxine therapy.150 Patients with thyroid cancer whose targetmay have a goiter. Titers of antithyroglobulin are elevated in 50% to TSH concentration is below the normal range almost uniformly require70% of patients, and almost all have antithyroid peroxidase anti- an increased dose to maintain their suppressed TSH levels, and theybodies.53 The goiter is firm and diffusely enlarged and painless, and the should be followed closely.150 After delivery, the dose should be reducedgland is infiltrated by lymphocytes and plasma cells. Many patients to pre-pregnancy levels in all patients, and the TSH concentrationwith Hashimoto thyroiditis are actually euthyroid but can subsequently should be measured 6 to 8 weeks later.develop hypothyroidism. The thyroid gland can be atrophic and the The topic of thyroid hormone and intellectual development hastest result for antibodies negative—so-called idiopathic hypothyroid- received widespread publicity and has been the subject of articles andism. Patients with other autoimmune disease also can develop Hashi- reviews in the past few years.128,151,152 In 1969, Man and Jones153 studiedmoto thyroiditis. a cohort of 1349 children and concluded that mild maternal hypothy- Other important and common causes of hypothyroidism include roidism alone was associated with lower IQ levels in the offspring. In131 I therapy, ablation for Graves disease, and thyroidectomy (e.g., for 1990, Matsuura and Konishi154 documented that fetal brain develop-thyroid cancer). Of patients who receive 131I therapy, 10% to 20% are ment is affected adversely when both mother and fetus have hypothy-hypothyroid within the first 6 months, and 2% to 4% become hypo- roidism caused by chronic autoimmune thyroiditis. With thethyroid each year thereafter.144 Hypothyroidism can result from sub- background of this information and the associations of iodine defi-acute viral thyroiditis and, much less commonly, from suppurative ciency, its consequent maternal hypothyroxinemia, and abnormal fetalthyroiditis. brain development, Haddow and associates151 conducted a study mea- Drugs known to inhibit the synthesis of thyroid hormones include suring TSH levels from stored samples in more than 25,000 pregnantthionamide, iodides, and lithium. Carbamazepine, phenytoin, and women. They located 62 women with high TSH levels and 124 matchedrifampin can increase thyroid clearance. Aluminum hydroxide, chole- women with normal values. Their 7- to 9-year-old children, none ofstyramine, and, most important, ferrous sulfate and sucralfate can whom had hypothyroidism as newborns, underwent 15 tests relatinginterfere with the intestinal absorption of thyroxine. to intelligence, attention, language, reading ability, school performance, Hypothyroidism resulting from hypothalamic or pituitary disease and visual-motor performance. The full-scale IQ in children of hypo-is rare but can occur in the setting of pituitary tumors, after pituitary thyroid women was 4 points lower (P = .06); 15% had scores of 85 orsurgery or irradiation, and in Sheehan’s syndrome and lymphocytic less compared with 5% of controls. The IQ of the children of 48hypophysitis, an autoimmune disease with a predilection for women, women whose hypothyroidism was not treated averaged 7 points lowerespecially in the setting of pregnancy (see Chapter 48). In secondary than the 124 controls (P = .005), and 19% had scores of 85 or lower.hypothyroidism, the TSH level may be low or normal, but the free T4 The researchers concluded that undiagnosed hypothyroidism canlevel is low. affect fetuses adversely and recommended screening for hypothyroid- ism in pregnancy. Fukushi and coworkers155 reported on such screen- ing in Japan and found hypothyroidism in 1 of 692 pregnancies.Treatment In a study by Pop and colleagues,156 even the presence of antithyroidHypothyroidism must be treated promptly, and a dose of 0.1 to 0.15 mg peroxidase antibodies in the maternal circulation was shown to haveof T4 per day, should be initiated. The dose is adjusted every 4 weeks deleterious effects on child development. In two similar studies, thyroiduntil the TSH concentration is in the lower end of the normal range. antibody–positive women had lower free T4 levels, and lower scores onIn women with little or no functioning thyroid tissue, a dose of 2 μg/ psychomotor tests were found in children of mothers whose free T4kg/day may be required. Women who are euthyroid on T4 need to be value was below the 5th and 10th percentiles as measured at 12 weeks’checked as soon as pregnancy is established; the dose should be adjusted gestation.157,158and rechecked in 4 to 8 weeks,145 because the requirements for thyroidhormone increase as early as the fifth week of gestation. Alternatively,the patient can be instructed to increase her dose by one extra doseper week and be checked a few weeks later. The amount of dose increase Subclinical Hypothyroidismmay depend on the cause. For example, women who have had totalthyroidectomy may need a greater increase than women with mild and Hypothyroxinemiahypothyroidism. Increased dosage requirements may plateau by the Subclinical hypothyroidism is defined as an elevated TSH level when20th week,145 but the need for increased dosage may be seen as late as the free T4 level is in the normal range. More than 90% of hypothyroid-
  • 14. 1008 CHAPTER 47 Thyroid Disease and Pregnancyism diagnosed in pregnancy is subclinical. Its estimated prevalence in that until the results of large, randomized trials become available, thethe general population is between 4% and 8.5%. The prevalence in extant evidence supports the benefits of T4 therapy, at least to reducepregnancy was 2.3% in a study of more than 17,000 women enrolled pregnancy loss and preterm delivery.69 This view was also held andfor prenatal care at 20 weeks’ gestation or less.159 In this study, pregnan- previously stated by Larsen.168 I recommend screening at least high-riskcies in patients with subclinical hypothyroidism were three times more women (as defined by ACOG and others) for TSH and free T4 levels.likely to be complicated by placental abruption, and the rate of preterm Subclinical hypothyroidism should be treated with thyroxine.birth (i.e., delivery at or before 34 weeks) was almost twofold higher. Adequate iodine intake should be ensured in those with isolated Hypothyroidism has been associated with impaired neurodevelop- hypothyroxinemia and treatment with thyroxine initiated if thement of the fetus.151 However, most of the patients in this study had a hypothyroxinemia does not resolve. I also recommend screeningTSH level of 10 mU/L or greater, and most had a low free T4 level; that patients who have delivered or had a miscarriage within 1 year of theis, they had overt rather than subclinical hypothyroidism. Nonetheless, index pregnancy, because postpartum or postmiscarriage thyroidthis study has prompted rigorous debate on the merits of universal disease is commonly found in the general population.screening of all pregnant women. The nuances of this debate werecarefully addressed by Casey.160 Although a panel from the AmericanThyroid Association, the Endocrine Society, and the American Associa-tion of Clinical Endocrinologists did not find sufficient evidence to Fetal and Neonatalrecommend routine screening in pregnancy in 2003, leaders of thesame societies later published a consensus statement, recommending Hypothyroidismscreening and treatment.161 The American College of Obstetricians and The relationship between iodine deficiency and fetal development wasGynecologists (ACOG) suggests it is premature to recommend univer- previously discussed. Severe neurologic deficits also occur in childrensal screening for hypothyroidism, because efficacy of treatment has not with congenital deficiency of thyroid hormone unrelated to iodinebeen demonstrated. The ACOG and the various endocrine associations deficiency. Neurologic development is impaired if infants are untreatedrecommend TSH measurements in women with a family history of before they are 3 months old. Screening of neonates for thyroidthyroid disease, prior thyroid dysfunction, symptoms of hypothyroid- hormone deficiency is mandatory in some states, and with earlyism, an abnormal thyroid gland, type 1 diabetes, or personal history therapy, their development is reasonably normal.29 Causes includeof autoimmune disease. However, targeting high-risk cases may miss thyroid agenesis and inborn errors of metabolism, such as peroxidasesignificant numbers with hypothyroidism, as was shown by Vaidya and deficiency. Congenital pituitary and hypothalamic hypothyroidismcoworkers.162 The investigators evaluated more than 1500 consecutive also occur but are rare. Thyroid hormone deficiency can result frompregnancies and found increased TSH levels in 40 women (2.6%). maternal blocking antibodies that are transferred to the fetus and thatAlthough the prevalence of high TSH levels was higher in the high-risk block TSH action or thyroid growth and development.169,170group (6.8% versus 1% in low-risk patients), 30% of women with high Gruner and associates171 reported a case of fetal goitrous hypothy-TSH levels were in the low-risk group. roidism in which fetal TSH levels were determined on three occasions Isolated maternal hypothyroxinemia (i.e., low free T4 and normal by cordocentesis to monitor weekly intra-amniotic administration ofTSH levels) during early pregnancy has been associated with impaired T4. This therapy was initiated to reduce the fetal goiter and polyhy-neurodevelopment of the fetus.158,163 The issue of detecting and treating dramnios (which it did) and to aid in fetal neurologic development.isolated maternal hypothyroxinemia is an area of equal uncertainty. They also reviewed other reported cases of such therapy and concludedUnfortunately, assays of true free T4 (e.g., equilibrium dialysis, ultra- that the optimal dose of T4 necessary to correct hypothyroidism couldfiltration, gel filtration) are expensive and labor intensive. Clinical more accurately be determined by cordocentesis than by measurementlaboratories use a variety of tests that estimate the free hormone con- of amniotic fluid hormone concentrations.centrations in the presence of protein-bound hormone, and they arebinding protein dependent to some extent. This negatively affects theaccuracy of free hormone assays.164 Free T4 assays usually result inlower values in late pregnancy.165,166 Nonetheless, in a “Clinical Perspec- Thyroid Nodules, Malignanttives” article in the Journal of Clinical Endocrinology and Metabolism,Morreale de Escobar and colleagues167 made a compelling case for Tumors, and Nontoxic Goiterscreening pregnant women for hypothyroxinemia, pointing out thatmaternal T4 (as opposed to T3) is the required substrate for the onto- in Pregnancygenetically regulated production of T3 in the amounts needed for Thyroid tumors are the most common endocrine neoplasms. Mostoptimal temporal and spatial development in different brain struc- nodules are benign hyperplastic (or colloid) nodules, but between 5%tures. This issue is important for women with relative iodine deficiency, and 20% are true neoplasms, which are benign follicular adenomasbecause T3 is preferentially synthesized. or carcinomas of follicular or parafollicular (C) cell origin. Nodular To address these dilemmas, the National Institute of Child Health thyroid disease is common, especially in women. A prospective studyand Human Development Maternal-Fetal Medicine Units Network found that the incidence of incipient thyroid nodules increased frominitiated a randomized trial of T4 treatment for subclinical hypothy- 15% in the first trimester to 24% after delivery, with an increase in theroidism or hypothyroxinemia diagnosed during pregnancy. The growth of existing nodules.172 There is no evidence that thyroid cancerprimary end point is the intellectual function of the children and sec- arises more frequently in pregnancy.ondary end points include determination of the frequency of preg- When a solitary or a dominant nodule is found within the thyroid,nancy complications, including preterm delivery, preeclampsia, biopsy is recommended. Cytopathologic diagnosis of fine-needle aspi-abruption, and stillbirth. ration biopsy (FNAB) in women between the ages of 15 and 40 years What do we do in the meantime? In an editorial by Brent67 accom- seen at the Mayo Clinic revealed benign findings in 64% and suspiciouspanying the paper on low-risk versus high-risk case finding, it was felt findings in 12%; FNAB was positive for cancer in 7% and nondiagnos-
  • 15. CHAPTER 47 Thyroid Disease and Pregnancy 1009tic in 17%.173 The topic of nodular thyroid disease in pregnancy wasalso reviewed. During a 10-year period, 40 pregnant women wereevaluated at the Mayo Clinic, and 39 had FNAB, 95% of which were Postpartum Thyroid Diseasediagnostic.174 Most (64%) were benign. Three (8%) were positive forpapillary thyroid cancer, and nine (23%) were suspicious for papillary Autoimmune thyroid disease, which is suppressed during pregnancy,cancer or a follicular (Hurthle cell) neoplasm. Comparable findings is exacerbated in the postpartum period. New-onset autoimmunewere reported by others.175 thyroid disease occurs in up to 10% of all postpartum women.39 Up to The principles of nodular thyroid disease diagnosis in pregnancy 60% of Graves patients in the reproductive years give a history ofresemble those for nonpregnant women. Serum TSH and free T4 levels postpartum onset.178 Most of the immune changes of pregnancy grad-should be obtained, and an FNAB should be performed on dominant ually return to normal in the 12-month postpartum period. Unlikenodules. Radionucleotide scanning is contraindicated, but ultrasound pregnancy, the major immune changes in T and B cells in the postpar-is often performed and can demonstrate other nodules, lymphade- tum period are overall T-cell deactivation, enhanced TH1-type T-cellnopathy, or abnormal calcification. FNAB is safe in pregnancy and can function, loss of tolerance for fetal alloantigens, enhanced IgG secre-be performed at any stage. If a nodule is benign, ultrasound can tion, and autoantibody secretion. Possible mechanisms explainingmonitor growth of the nodule during pregnancy. If the nodule is suspi- postpartum autoimmune exacerbation suggested by Davies39 includecious for a follicular or Hurthle cell neoplasm, it usually represents a a reduced number of fetal cells, leading to loss of maternal tolerance10% to 15% risk of malignancy. It is generally recommended that to remaining microchimeric cells, and a loss of placental major histo-surgery be performed after delivery, but if a malignancy is diagnosed compatibility complex-peptide complexes, which were inducing T-cellin early pregnancy, surgery may be performed in the second trimester anergy during pregnancy.for the patient needing reassurance. If the FNAB result is positive orsuspicious for papillary thyroid cancer, the risk is high (50% for suspi-cious and 100% for positive), and neck exploration should be per- Postpartum Graves Diseaseformed at the soonest safe date. Figure 47-7 outlines the decision-making The onset of Graves disease after delivery correlates with the develop-process. ment of TSIs. Peak antibody production is observed 3 to 6 months after The impact of pregnancy on papillary thyroid cancer was evaluated delivery. Almost all patients with persisting TSIs at the end of preg-by Moosa and Mazzaferri.176 They compared outcomes in pregnant nancy have a recurrence of Graves if antithyroid drugs are withdrawn.and nonpregnant women and found no difference in the rates of recur- The prevalence of postpartum Graves disease, which can be transientrence, distant spread, or cause-specific mortality. Outcomes were or persistent, is estimated at 11% of those with postpartum thyroidsimilar when neck surgery was performed during or after pregnancy. dysfunction.179A similar conclusion was reached in a study of thyroid cancer casesfrom the New Mexico Tumor Registry.177 If medullary thyroid canceris suspected, early surgery is advised. Postpartum Thyroiditis The topic of postpartum thyroiditis (PPT) has been the focus of numerous reviews.39,179-183 For the diagnosis of PPT, there must be a documented abnormal TSH level (suppressed or elevated) during the Solitary thyroid nodule first postpartum year in the absence of a positive result for TSIs normal TSH (excluding Graves) or a toxic nodule. ultrasound: solid or semi-cystic Classically, PPT manifests with a transient hyperthyroid phase of 6 weeks to 6 months after delivery. A hypothyroid phase follows and can last up to 1 year after delivery. Figure 47-8 schematically demonstrates FNAB of palpable nodule this and the accompanying changes in serum thyroid antibody con- centrations. A review of 11 studies of PPT184 revealed that only 26% of patients presented in this classic manner. Most patients present with hyperthyroidism alone (38%) or hypothyroidism alone (36%). The Benign Frankly malignant Suspicious for incidence of PPT is 6% to 9%. It is an autoimmune disorder, and or suspicious for follicular patients with type 1 diabetes have an increased incidence, which was papillary cancer neoplasm found to be approximately 25% in two North American studies.185,186 Women with a history of PPT in a prior pregnancy had a 69% recur- rence rate in the subsequent pregnancy. Observe 1st or 2nd TM 3rd TM Operate Symptoms of the hyperthyroid phase of PPT include fatigue, pal- postpartum pitations, heat intolerance, and nervousness. This destructive hyper- thyroid phase always has a limited duration (a few weeks to a fewReaspirate Operate in Operate months). Although β-blockers may reduce symptoms, antithyroidif enlarges 2nd TM postpartum medications have no role to play. The hypothyroid phase can be marked by fatigue, hair loss, depres- sion, impairment of concentration, and dry skin. The hypothyroidFIGURE 47-7 Evaluation of thyroid nodules. The decision-makingprocess is outlined for management of a solitary thyroid nodule in phase frequently requires treatment, but it is reasonable to wean thepregnancy. (Adapted from Tan GH, Gharib H, Goellner JR, et al: patient off therapy 6 months after initiation. Some authorities recom-Management of thyroid nodules in pregnancy. Arch Intern Med mend maintaining T4 therapy in these patients until the childbearing156:2317, 1996. Copyright © 1996, American Medical Association. All years are over and then attempting to wean them off the therapy a yearrights reserved.) after the last delivery.
  • 16. 1010 CHAPTER 47 Thyroid Disease and Pregnancy FIGURE 47-8 Postpartum thyroiditis and changes in thyroid antibody concentrations. A, Postpartum thyroiditis manifests with a transient hyperthyroid phase, during which serum levels of thyroxine (T4) are elevated. A hypothyroid phase follows. B, Serum thyroid antibody levels fluctuate during and after pregnancy. (From Smallridge RC, Fein HC, Hayship CC: Postpartum thyroiditis. Bridge Newslett Thyroid Found Am 3:3, 1988.) The thyroid gland is enlarged in PPT, and thyroid hypoechogenicity presence of antibody and depression was found, and they concludedappears to be the characteristic ultrasonographic finding.187 PPT is an that antibody status during pregnancy was an important predictor ofautoimmune disorder, and there is an association between it and HLA- PPT but not of depression. In a subsequent study, Pop and associates193DR3, HLA-DR4, and HLA-DR5 status. The lymphocytic infiltration is reported an association between thyroid antibodies and depression insimilar to that seen in Hashimoto thyroiditis. Stagnaro-Green182 postmenopausal women.reported that 33% of women who were antithyroid antibody positive In summary, the data suggest some association for PPT, thyroidin the first trimester of pregnancy had PPT, compared with 3% of antibodies, and depression. Of the four clinical trials, two demon-women who were antibody negative. strated an association between PPT and depression, whereas two dem- The laboratory hallmarks of PPT, which is a destructive process, are onstrated an association between thyroid antibodies and depression.positive test results for antithyroid antibodies (i.e., antithyroglobulin The role of potential interventions such as T4 therapy has not beenand antithyroid peroxidase), suppressed TSH levels, and high T4 levels evaluated systematically.(released from destroyed thyroid cells) in the hyperthyroid phase,along with a profoundly suppressed radioactive iodine uptake (contra- Hypothyroidism and Postpartum Thyroiditisindicated in a breastfeeding woman). The absence of TSIs usually rules Recovery of thyroid function in women with PPT is not universal, andout Graves disease, which can also be distinguished by high radioactive some women remain permanently hypothyroid. In a study of 44iodine uptake. women with PPT with a mean follow-up of 8.7 years after delivery, Tachi and associates194 reported that 77% of the women recoveredDepression and Postpartum Thyroiditis during the first postpartum year and remained euthyroid. PermanentDepression and PPT are common postpartum events.188 Four large- hypothyroidism developed in the other 23%; one half of these neverscale studies have been performed to evaluate their association. Harris recovered euthyroid function after the initial postpartum insult, andand colleagues189 evaluated 147 women (65 were thyroid antibody the other half developed hypothyroidism during the years of follow-positive, and 82 were negative) at 6 to 8 weeks after delivery for thyroid up. A 23% incidence of permanent hypothyroidism at long-termstatus and depression. Although there was a positive correlation follow-up (mean, 3.5 years) was also reported by Othman and cowork-between PPT and postpartum depression, there was no association ers.195 It is recommended that women with a history of PPT be evalu-between antibody positivity and depression. ated annually for the possible development of hypothyroidism. Pop and associates190 evaluated 293 women during the third trimes-ter and then every 6 weeks up to 34 weeks after delivery. They found Thyroiditis after Abortionthat 38% of women with PPT experienced depression compared with Several studies have described cases of thyroiditis occurring after an9.5% of women in a matched control group, and the difference was abortion.196,197 Neither the incidence nor clinical sequelae are known.highly significant. Status of antibodies was not reported. In the case of Stagnaro-Green,196 the patient developed transient hypo- Harris and coauthors191 investigated the association between thyroidism after a spontaneous miscarriage. After a subsequent termdepression and PPT in 232 women (110 were thyroid antibody posi- delivery, the patient became severely hypothyroid, and this conditiontive). The women had psychiatric assessment five times during the first remained permanent.28 weeks after delivery. No association was found between PPT anddepression, but an association was found between depression and anti- Prevention and Screening ofbody positivity. They concluded that 4% of women experience post- Postpartum Thyroiditispartum depression that has an autoimmune origin. Levothyroxine (0.1 mg daily) or iodide (0.15 mg daily) was adminis- Pop and colleagues192 performed a further analysis of the same 293 tered for 40 weeks after delivery to women who were thyroid antibodywomen in their earlier study; antibody status was determined during positive during pregnancy. A control group of antibody-negativethe pregnancy, but only a slightly increased association between the women received no treatment. The incidence of PPT was similar in all
  • 17. CHAPTER 47 Thyroid Disease and Pregnancy 1011three groups, and the degree of postpartum elevation of thyroid per- 21. Radunovic N, Domez Y, Mandelbrot L, et al: Thyroid function in fetusoxidase antibodies was indistinguishable in the three groups.198 and mother during the second half of normal pregnancy. Biol Neonate Whether screening for PPT is worthwhile is a contentious issue. A 59:139, 1991.“Therapeutic Controversy” article in the Journal of Clinical Endocrinol- 22. LaFranchi S: Thyroid function in the preterm infant. Thyroid 9:71, 1999. 23. Fisher DA: Hypothyroxinemia in premature infants: Is thyroxine treat-ogy and Metabolism addressed this topic.179 Arguments for and against ment necessary? Thyroid 9:715, 1999.screening were presented. It was suggested that screening and treat- 24. Bernal J, Perkonen F: Ontogenesis of the nuclear 3,5,3′-triiodothyroninement of symptomatic hypothyroidism would improve the quality of receptor in the human fetal brain. Endocrinology 114:677, 1984.life of the mother, and the importance of recognizing postpartum 25. Santini F, Chiovato L, Ghirri P, et al: Serum iodothyronine in the humandepression was stressed. Contradicting arguments posited that the fetus and the newborn: Evidence for an important role of placenta in fetaloptimal screening strategy was undefined and that no cost-benefit thyroid hormone homeostasis. J Clin Endocrinol Metab 84:493, 1999.analysis has been performed. It is agreed that women who present with 26. Vulsma T, Gons MH, de Vijlder JJ: Maternal-fetal transfer of thyroxine insymptoms should have a TSH assay performed. High-risk women (i.e., congenital hypothyroidism due to a total organification defect or thyroidwomen with a history of PPT and women with type 1 diabetes) should agenesis. N Engl J Med 321:13, 1989.be screened.186,199 27. Delange F, de Vilder JJ, Morreale de Escobar G, et al: Significance of early diagnostic data in congenital hypothyroidism: Report of the Subcommit- tee on Neonatal Hypothyroidism of the European Thyroid Association. In Delange F, Fisher DA, Glinoer D (eds): Research in Congenital Hypothy-References roidism. New York, Plenum Press, 1989, pp 225-234. 1. Casey BM, Leveno KJ: Thyroid disease in pregnancy. Obstet Gynecol 28. Kester MHA, Martinez de Mena R, Obregon MJ, et al: Iodothyronine levels 108:1283, 2006. in the human developing brain: Major regulatory roles of iodothyronine 2. LeBeau SO, Mandel SJ: Thyroid disorders during pregnancy. Endocrinol deiodinases in different areas. J Clin Endocrinol Metab 9:3117, 2004. Metab Clin North Am 35:117, 2006. 29. Fisher DA, Polk DH: Development of the thyroid. Baillieres Clin Endocri- 3. Abalovich M, Amino N, Barbour LA, et al: Management of thyroid nol Metab 3:627,1989. dysfunction during pregnancy and postpartum: An Endocrine Society 30. Fisher DA, Dussault JH, Sack J, et al: Ontogenesis of hypothalamic- clinical practice guideline. J Clin Endocrinol Metab 92(suppl):S1, pituitary-thyroid function and metabolism in man, sheep and rat. Recent 2007. Prog Horm Res 3:59, 1977. 4. Brennan MD, Bahn RS: Thyroid hormones and illness. Endocr Pract 31. Polk DH: Thyroid hormone effects on neonatal thermogenesis. Semin 4:396, 1998. Perinatol 12:151, 1988. 5. DeGroot LJ: Dangerous dogmas in medicine: The non-thyroidal illness 32. Reuss ML, Paneth N, Pinto-Martin JA, et al: The relation of transient syndrome. J Clin Endocrinol Metab 84:151, 1999. hypothyroxinemia in preterm infants to neurologic development at two 6. Brent GA: The molecular basis of thyroid hormone action. N Engl J Med years of age. N Engl J Med 443:821, 1996. 331:847, 1994. 33. Vulsma Y, Kok JK: Prematurity-associated neurological and development 7. Glinoer D: What happens to the normal thyroid during pregnancy? abnormalities and neonatal thyroid function. N Engl J Med 3343:857, Thyroid 9:631, 1999. 1996. 8. Glinoer D, De Nayer P, Robyn C, et al: Serum levels of intact human cho- 34. Williams FLR, Mires GJ, Barnett C, et al: Transient hypothyroxinemia in rionic gonadotropin (hCG) and its free α and β subunits, in relation to preterm infants: The role of cord sera thyroid hormone levels adjusted for maternal thyroid stimulation during normal pregnancy. J Endocrinol prenatal and antepartum factors. J Clin Endocrinol Metab 90:4599, 2005. Invest 16:881, 1993. 35. Burrow GN, May PB, Spaulding SW, et al: TRH and dopamine interac- 9. Grün JP, Meuris S, DeNayer P, et al: The thyrotropic role of human cho- tions affecting pituitary hormone secretion. J Clin Endocrinol Metab rionic gonadotropin (hCG) in the early stages of twin (versus single) 45:65, 1977. pregnancy. Clin Endocrinol 46:719, 1997. 36. Roti E, Gnudi A, Braverman LE: The placental transport, synthesis and10. Burrow GN, Fisher DA, Larsen PR: Maternal and fetal thyroid function. metabolism of hormones and drugs, which affect thyroid function. Endocr N Engl J Med 331:1072, 1994. Rev 4:131, 1983.11. Glinoer D, De Nayer P, Delange F, et al: A randomized trial for the treat- 37. Ballard RA, Ballard PL, Creasy RK, et al: Respiratory disease in very- ment of mild iodine deficiency during pregnancy: Maternal and neonatal low-birthweight infants after prenatal thyrotropin-releasing hormone effects. J Clin Endocrinol Metab 80:258, 1995. and glucocorticoid. Lancet 339:510, 1992.12. Glinoer D: The regulation of thyroid function in pregnancy: Pathways of 38. Romaguera J, Ramirez M, Adamsons K: Intra-amniotic thyroxine to accel- endocrine adaptation from physiology to pathology. Endocr Rev 18:404, erate fetal maturation. Semin Perinatol 17:260, 1993. 1997. 39. Davies TF: The thyroid immunology of the postpartum period. Thyroid13. Levy RP, Newman M, Rejah LS, et al: The myth of goiter in pregnancy. 9:675, 1999. Am J Obstet Gynecol 137:701, 1980. 40. Weetman AP: The immunology of pregnancy. Thyroid 9:643, 1999.14. Nelson M, Wickos GG, Caplan RH, et al: Thyroid gland size in pregnancy. 41. Nelson JL, Hughes KA, Smith AG, et al: Maternal fetal disparity in HLA J Reprod Med 32:888, 1987. class II alloantigens and the pregnancy induced amelioration of rheuma-15. Brander A, Kivsaari L: Ultrasonography of the thyroid during pregnancy. toid arthritis. N Engl J Med 329:466, 1993. J Clin Ultrasound 17:403, 1989. 42. Buyon JP, Nelson JL, Lockshine MD: The effects of pregnancy on autoim-16. Halnan KE: The radioiodine uptake of the human thyroid in pregnancy. mune thyroid diseases. Clin Immunol Immunopathol 79:99, 1996. Clin Sci 17:281, 1958. 43. Confavreuz C, Hutchinson M, Hours MH, et al: Rate of pregnancy related17. Abdoul-Khair SA, Crooks J, Turnbull AC, et al: The physiological changes relapse in multiple sclerosis. New Engl J Med 339:285, 1998. in thyroid function during pregnancy. Clin Sci 27:195, 1964. 44. Piccinini MP, Giudizi MG, Biagiotti R, et al: Progesterone favors the devel-18. Ferris TF: Renal disease. In Burrow GN, Ferris TF (eds): Medical Compli- opment of human T helper cells producing Th2-type cytokines and pro- cations During Pregnancy. Philadelphia, WB Saunders, 1988, p 277. motes both IL-4 production and membrane CD30 expression in19. Beckers C: Iodine economy in and around pregnancy. In Beckers C, Rein- established Th1 cell clones. J Immunol 155:128, 1995. wein D (eds): The Thyroid and Pregnancy. New York, John Wiley and 45. Ain KB, Mori Y, Refetoff F: Reduced clearance rate of thyroxine-binding Sons, 1992. globulin (TBG) with increased sialylation: A mechanism for estrogen20. Glinoer D, Delange F: The potential repercussions of maternal, fetal and induced elevation of serum TBG concentration. J Clin Endocrinol Metab neonatal hypothyroxinemia on the progeny. Thyroid 10:871, 2000. 65:689, 1987.
  • 18. 1012 CHAPTER 47 Thyroid Disease and Pregnancy46. Dashe JS, Casey BM, Wells CE, et al: Thyroid stimulating hormone in 73. Sioka C, Kouaklis G, Zafirakis, et al: Menstrual cycle disorders after therapy singleton and twin pregnancy: Importance of gestational age-specific ref- with iodine-131. Fertil Steril 86:625, 2006. erence ranges. Obstet Gynecol 106:753, 2005 74. Smith MB, Xue H, Takahashi H, et al: Iodine 131I thyroid ablation in female47. Glinoer D, Soto MF, Bouroux P, et al: Pregnancy in patients with mild children and adolescents: Long term risk of infertility and birth defects. thyroid abnormalities: Maternal and neonatal repercussions. J Clin Endo- Ann Surg Oncol 1:128, 1994. crinol Metab 73:421, 1991. 75. Schlumberger M, deVathaire F, Ceccarelli C, et al: Exposure to radioactive48. Weintraub BD: Inappropriate secretion of thyroid-stimulating hormone. iodine 131I for scintigraphy or therapy does not preclude pregnancy in Ann Intern Med 95:339, 1981. thyroid cancer patients. J Nucl Med 37:606, 1996.49. Anselmo J, Kay T, Dennis K, et al: Resistance to thyroid hormone does not 76. Gorman CA: Radio iodine and pregnancy. Thyroid 9:721, 1999. abrogate the transient thyrotoxicosis associated with gestation: Report of 77. Berlin L: Malpractice issues in radiology. Iodine 131I and the pregnant a case. J Clin Endocrinol Metab 86:4273, 2001. patient. Am J Radiol 176:869, 2001.50. Anselmo J, Cao D, Karrison T, et al: Fetal loss associated with excess 78. Fernandez-Soto ML, Jovanovic LG, Gonzalez-Jimenez A, et al: Thyroid thyroid hormone exposure. JAMA 292:691, 2004. function during pregnancy and the postpartum period iodine metabolism51. Mariotti S, Chiovato L, Vitti P, et al: Recent advances in the understanding and disease status. Endocr Pract 4:97, 1998. of humoral and cellular mechanisms implicated in thyroid autoimmune 79. Seely BL, Burrow GN: Thyrotoxicosis in pregnancy. Endocrinologist disorders. Clin Immunol Immunopathol 50:573, 1989. 7:409, 1991.52. Learoyd DL, Fund HYM, McGregor AM: Postpartum thyroid dysfunction. 80. Costagliola S, Morgenthaler NG, Hoermann R, et al: Second generation Thyroid 2:73, 1992. assay for thyrotoxicosis receptor and bodies has superior diagnostic sen-53. Weetman AP, McGregor AM: Autoimmune thyroid disease: Further devel- sitivity for Graves disease. J Clin Endocrinol Metab 84:90, 1999. opments in our understanding. Endocr Rev 15:788, 1994. 81. Varner MW: Autoimmune disorders and pregnancy. Semin Perinatol54. Bartalena L, Bogazzi F, Braverman LE, et al: Effect of amiodarone admin- 15:238, 1991. istration during pregnancy on neonatal thyroid function and subsequent 82. Davis LE, Lucas MJ, Hankins GDV, et al: Thyrotoxicosis complicating neurodevelopment. J Endocrinol Invest 24:116, 2001. pregnancy. Am J Obstet Gynecol 160:63, 1989.55. Wartofsky L, Burman KD: Alterations in thyroid function in patients 83. Momotani N, Ito K: Treatment of pregnant patients with Basedow’s with systemic illness: The “euthyroid sick syndrome.” Endocr Rev 3:164, disease. Exp Clin Endocrinol 97:268, 1991. 1982. 84. Millar LK, Wing DA, Leung AS, et al: Low birth weight and preeclampsia56. Brent GA, Hershman JM: Thyroxine therapy in patients with severe non- in pregnancies complicated by hyperthyroidism. Obstet Gynecol 84:946, thyroidal illnesses and low serum thyroxine concentration. J Clin Endo- 1994. crinol Metab 63:1, 1986. 85. Cooper DS: Antithyroid drugs. N Engl J Med 352:905, 2005.57. Winters SJ, Berga SL: Gonadal dysfunction in patients with thyroid disease. 86. Clark SM, Saade GR, Sodgrass WR, et al: Pharmacokinetics and pharma- Endocrinologist 7:167, 1997. cotherapy of thionamides in pregnancy. Ther Drug Monit 28:477, 2006.58. Krassas GE: Thyroid disease and female reproduction. Fertil Steril 74:1063, 87. Momotani N, Noh J, Oyanagi H, et al: Antithyroid drug therapy for 2000. Graves’ disease during pregnancy. N Engl J Med 315:24, 1986.59. Trokoudes KM, Skordis N, Picolos MK: Infertility and thyroid disorders. 88. Kung AWC, Jones BM: A change from stimulatory to blocking antibody Curr Opin Obstet Gynecol 18:446, 2006. activity in Graves’ disease during pregnancy. J Clin Endocrinol Metab60. Krassas GE, Pontikides N, Kaltsas TH, et al: Menstrual disturbances in 8:514, 1998. thyroidism. Clin Endocrinol 40:641, 1994. 89. Cooper DS, Goldminz D, Levin AA, et al: Agranulocytosis associated with61. Akande EO, Hockaday TD: Plasma estrogen and luteinizing hormone antithyroid drugs. Ann Intern Med 98:26, 1983. concentrations in thyrotoxic menstrual disturbances. Proc R Soc Med 90. Mortimer RH, Cannell GR, Addison RS, et al: Methimazole and propyl- 65:789, 1972. thiouracil equally cover the perfused human term placental lobule. J Clin62. Tanaka T, Tamin H, Kuma K, et al: Gonadotropin response to luteinizing Endocrinol Metab 82:3099, 1997. hormone releasing hormone in hyperthyroid patients with menstrual dis- 91. Milham S, Elledge W: Maternal methimazole and congenital defects in turbances. Metabolism 30:323, 1981. children. Teratology 5:525, 1972.63. Wilansky DL, Greisman B: Early hypothyroidism in patients with menor- 92. Van Djihe UP, Heydendael RJ, De Kleine MR: Methimazole, carbimazole rhagia. Am J Obstet Gynecol 160:673, 1989. and congenital skin defects. Ann Intern Med 106:60, 1987.64. Del Pozo E, Wyss H, Tolis G, et al: Prolactin and deficient luteal function. 93. Martinez-Frias ML, Cereijo A, Rodriguez-Pinella E, et al: Methimazole in Obstet Gynecol 53:282, 1979. animal feed and congenital aplasia cutis. Lancet 399:742, 1992.65. Thomas R, Reid RL: Thyroid disease and reproductive dysfunction. Obstet 94. Johnsson E, Larsson G, Ljunggren M: Severe malformations in infants Gynecol 70:789, 1987. born to hyperthyroid women on methimazole. Lancet 350:1520, 1997.66. Wasserstrum N, Anania CA: Perinatal consequences of maternal hypothy- 95. Clementi M, DiGianantonio E, Pelo E, et al: Methimazole embryopathy: roidism in early pregnancy and inadequate replacement. Clin Endocrinol Delineation of the phenotype. Am J Med Genet 83:43, 1999. 42:343, 1997. 96. Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al: Adverse effects of67. Brent GA: Diagnosing thyroid dysfunction in pregnant women: Is case prenatal methimazole exposure. Teratology 64:262, 2001. finding enough? J Clin Endocrinol Metab 92:39, 2007. 97. Wolf D, Foulds N, Daya H: Antenatal carbimazole and choanal atresia: A68. Montoro MN: Management of hypothyroidism during pregnancy. Clin new embryopathy Arch Otolaryngol Head Neck Surg 132:1009, 2006. Obstet Gynecol 40:65, 1997. 98. Phoojaroenchanachai M, Sriussadaporn S, Peerapatdir T, et al: Effect of69. Negro R, Fomoso G, Manieri T, et al: Levothyroxine treatment in euthy- maternal hyperthyroidism during late pregnancy on the risk of neonatal roid pregnant women with autoimmune thyroid disease: Effects on low birth weight. Clin Endocrinol 54:365, 2001. obstetrical complications. J Clin Endocrinol Metab 91:2587, 2006. 99. Mitsuda N, Tamaki H, Amino N, et al: Risk factors for development dis-70. Glinoer D: Miscarriage in women with positive anti-TPO antibodies: Is orders in infants born to women with Graves’ disease. Obstet Gynecol thyroxine the answer [editorial]? J Clin Endocrinol Metab 91:2500, 80:359, 1992. 2006. 100. Wing DA, Millar LK, Kooings PP, et al: A comparison of propylthiouracil71. Greig WR: Radioactive iodine therapy for thyrotoxicosis. Br J Surg 758:765, versus methimazole in the treatment of hyperthyroidism in pregnancy. 1973. Am J Obstet Gynecol 170:90, 1994.72. Safa AM, Schumacher OP, Rodriguez-Antunez A: Long-term follow-up 101. Thorpe-Beeston JG, Nicolaides KH, Felton CV, et al: Maturation of the results in children and adolescents treated with radioactive iodine (131I) secretion of thyroid hormone and thyroid-stimulating hormone in the for hyperthyroidism. N Engl J Med 292:167, 1975. fetus. N Engl J Med 324:532, 1991.
  • 19. CHAPTER 47 Thyroid Disease and Pregnancy 1013102. Kampmann JP, Johansen K, Hansen JM, et al: Propylthiouracil in human 129. Glinoer D: Pregnancy and iodine. Thyroid 11:471, 2001. milk: Revision of a dogma. Lancet 1:736, 1980. 130. Dunn JT, Delange F: Damaged reproduction: The most important103. Azzizi F: Effect of methimazole treatment of maternal thyrotoxicosis on consequence of iodine deficiency. J Clin Endocrinol Metab 86:2360, thyroid function in breast-feeding infants. J Pediatr 128:855, 1996. 2001.104. Isley WL, Dahl S, Gibbs H: Use of esmolol in managing a thyrotoxic 131. Delange F, de Benoist B, Pretell E, et al: Iodine deficiency in the world: patient needing emergency surgery. Am J Med 89:122, 1990. Where do we stand at the turn of the century? Thyroid 11:437, 2001.105. Burrow GN: The management of thyrotoxicosis in pregnancy. N Engl J 132. Hollowell JG, Staehling NW, Hannon WH, et al: Iodine nutrition in the Med 313:562,1985. United States. Trends from public health implications: Iodine excretion106. Burch HB, Wartofsky L: Life threatening thyrotoxicosis: Thyroid storm. data from National Health and Nutrition Examination Surveys I and III Endocrinol Metab Clin North Am 22:263, 1993. (1971-1974 and 1988-1994). J Clin Endocrinol Metab 83:3401, 1998.107. Waltman PA, Brewer JM, Lobert S: Thyroid storm during pregnancy. A 133. Pharoah PQ, Butterfield IH, Hetzel BS: Neurological damage to the fetus medical emergency. Crit Care Nurse 24:74, 2004. resulting from severe iodine deficiency during pregnancy. Lancet 1:308,108. Sheffield JS, Cunningham FG: Thyrotoxicosis and heart failure that com- 1971. plicate pregnancy. Am J Obstet Gynecol 190:211, 2004. 134. Vanderpas JB, Contempré B, Dvale NL, et al: Iodine and selenium defi-109. Casey BM, Dashe JS, Wells CE, et al: Clinical hyperthyroidism and preg- ciency associated with cretinism in Northern Zaire. Am J Clinic Nutr nancy outcomes. Obstet Gynecol 107:337, 2006. 52:1087, 1990.110. Zimmerman D: Fetal and neonatal hyperthyroidism. Thyroid 9:727, 135. Bleichrodt N, Born MP: A meta-analysis of research on iodine and its 1999. relationship to cognitive development. In Stanbury JB (ed): The Damaged111. Clavel S, Madec A, Bornet H, et al: Anti TSH-receptor antibodies in preg- Brain of Iodine Deficiency. New York, Cognizant Communication, 1994, nant patients with autoimmune thyroid disorder. BJOG 97:1003, 1990. p 195.112. Zakarija M, McKenzie JM: Pregnancy-associated changes in thyroid- 136. Xue-Yi C, Xin-Min J, Zhi-Hong D, et al: Time of vulnerability of the brain stimulating antibody of Graves’ disease and the relationship to neonatal to iodine deficiency in endemic cretinism. N Engl J Med 331:1739, 1994. hyperthyroidism. J Clin Endocrinol Metab 57:1036, 1983. 137. Yasuda T, Ohnishi H, Wataki K, et al: Outcome of a baby born from a113. Becks GP, Burrow G: Thyroid disease and pregnancy. Med Clin North Am mother with acquired juvenile hypothyroidism having undetectable 75:121, 1991. thyroid hormone concentrations. J Clin Endocrinol Metab 84:2630,114. Houck JA, Davis RE, Sharma HM: Thyroid-stimulating immunoglobulin 1999. as a cause of recurrent intrauterine fetal death. Obstet Gynecol 71:1018, 138. Utiger RD: Iodine nutrition: More is better. N Engl J Med 354:26, 2006. 1988. 139. Klein RZ, Haddow JE, Faix JD, et al: Prevalence of thyroid deficiency in115. Yoshimoto M, Nakayama Itoi, Baba P, et al: A case of neonatal McCune- pregnant women. Clin Endocrinol 35:41, 1991. Albright syndrome with Cushing syndrome and hyperthyroidism. Acta 140. Kamijo K, Saito T, Saito M, et al: Transient subclinical hypothyroidism in Pediatr Scand 89:984, 1991. early pregnancy. Endocrinol Jpn 37:387, 1990.116. Kopp P, Van Sande J, Parmer J, et al: Brief report: Congenital hyperthyroid- 141. Leung AS, Millar LK, Koonings PP, et al: Perinatal outcome in hypothyroid ism caused by a mutation in the thyrotropin receptor gene. N Engl J Med patients. Obstet Gynecol 81:349, 1993. 322:150, 1995. 142. Davis LE, Leveno KJ, Cunningham FG: Hypothyroidism complicating117. Hershman JM: Human chorionic gonadotropin and the thyroid: pregnancy. Obstet Gynecol 72:108, 1988. Hyperemesis gravidarum and trophoblastic tumors. Thyroid 9:653, 143. Jovanovic-Peterson L, Peterson CM: De novo clinical hypothyroidism in 1999. pregnancies complicated by type I diabetes, subclinical hypothyroidism118. Talbot JA, Lambert A, Anobile LJ, et al: The nature of human chorionic and proteinuria. Am J Obstet Gynecol 159:442, 1988. gonadotropin glycoforms in gestational thyrotoxicosis. Clin Endocrinol 144. Werner S: Modification of the classification of eye changes of Graves’ 55:33, 2001. disease: Recommendation of the Ad Hoc Committee of the American119. Bashiri A, Neumann L, Maymon E, et al: Hyperemesis gravidarum: Epi- Thyroid Association. J Clin Endocrinol Metab 44:203, 1977. demiologic features, complications and outcome. Eur J Obstet Gynecol 145. Alexander EK, Marqusee E, Lawrence J, et al: Timing and magnitude of Reprod Biol 63:135, 1995. increases in levothyroxine requirements during pregnancy in women with120. Goodwin TM, Montoro M, Mestman JH: The role of chorionic gonado- hypothyroidism. N Engl J Med 351:241, 2004. tropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin 146. Mandel SJ, Larsen PR, Seely EW, et al: Increased need for thyroxine during Endocrinol Metab 75:1333, 1992. pregnancy in women with primary hypothyroidism. N Engl J Med 323:91,121. Goodwin TM, Montoro M, Mestman JH: Transient hyperthyroidism and 1990. hyperemesis gravidarum: Clinical aspects. Am J Obstet Gynecol 167:648, 147. Kaplan MM: Monitoring thyroxine treatment during pregnancy. Thyroid 1992. 2:147, 1992.122. Wilson R, McKillop JH, MacLean M, et al: Thyroid function tests are rarely 148. Kaplan MM: Management of thyroxine therapy during pregnancy. Endocr abnormal in patients with severe hyperemesis gravidarum. Clin Endocri- Pract 2:281, 1996. nol (Oxf) 37:331, 1992. 149. Mestman JH: Thyroid disease in pregnancy other than Graves’ and post123. Pekary AE, Jackson IM, Goodwin TM, et al: Increased in vitro thyrotropic partum thyroid dysfunction. Endocrinologist 9:294, 1999. activity of partially sialated human chorionic gonadotropin extracted 150. Brent GA: Maternal hypothyroidism recognition and management. from hydatidiform moles of patients with hyperthyroidism. J Clin Endo- Thyroid 9:661, 1999. crinol Metab 76:70, 1993. 151. Haddow JE, Palomaki GE, Alan WC, et al: Maternal thyroid deficiency124. Morgan LS: Hormonally active gynecologic tumors. Semin Surg Oncol during pregnancy and subsequent neuropsychological development of the 6:83, 1990. child. N Engl J Med 341:549, 1999.125. Nader S, Mastrobattista J: Recurrent hyperthyroidism in consecutive preg- 152. Klein RZ, Mitchell ML: Maternal hypothyroidism and child development. nancies characterized by hyperemesis. Thyroid 6:465, 1996. Horm Res 52:55, 1999.126. Rodien P, Bremont C, Sanson M-LR, et al: Familial gestational hyperthy- 153. Man EB, Jones WS: Thyroid function in human pregnancy. V. Incidence roidism caused by a mutant thyrotropic receptor hypersensitive to human of maternal serum low butanol-extractable iodines and of normal gesta- chorionic gonadotropin. N Engl J Med 339:1823, 1998. tional TBG and TBPA capacities: Retardation of 8-month old infants. Am127. Mariotti S, Martino E, Cupini C: Low serum thyroglobulin as a clue to the J Obstet Gynecol 104:898, 1969. diagnosis of thyrotoxicosis factitia. N Engl J Med 307:410, 1982. 154. Matsuura N, Konishi J: Transient hypothyroidism in infants born to128. Lazarus JH: Thyroid hormone and intellectual development: A clinician’s mothers with chronic thyroiditis—a nationwide study of 23 cases. Endo- view. Thyroid 9:659, 1999. crinol Jpn 37:767, 1990.
  • 20. 1014 CHAPTER 47 Thyroid Disease and Pregnancy155. Fukushi M, Honma IC, Fujita K: Maternal thyroid deficiency during preg- 178. Janssen R, Dahlberg PA, Winsa B, et al: The postpartum period constitutes nancy and subsequent neuropsychological development of the child an important risk for the development of clinical Graves’ disease in young [letter]. N Engl J Med 341:556, 1999. women. Acta Endocrinol 116:321, 1987.156. Pop VJM, deVries E, van Baar AL, et al: Maternal thyroid peroxidase anti- 179. Amino N, Tada H, Hidaka Y, et al: Therapeutic controversy. Screening for bodies during pregnancy: A marker of impaired child development? J Clin postpartum thyroiditis. J Clin Endocrinal Metab 84:1813, 1999. Endocrinol Metab 80:3561, 1995. 180. Lazarus JH: Clinical manifestations of postpartum thyroid disease.157. Lazarus JH, Aloa A, Parkes AB, et al: The effect of anti-TPO antibodies on Thyroid 9:685, 1999. thyroid function in early gestation: Implications for screening. Presented 181. Lucas A, Pizarro E, Granada ML, et al: Postpartum thyroiditis: Epidemiol- at the American Thyroid Association meeting, Portland, Oregon, 1998. ogy and clinical evolution in a non-selected population. Thyroid 10:71,158. Pop VJM, Kuijpens JV, van Baar AL, et al: Low maternal FT4 concentra- 2000. tions during early pregnancy associated with impaired psychomotor 182. Stagnaro-Green AS: Recognizing, understanding and treating postpartum development in infancy. Clin Endocrinol 50:149, 1999. thyroiditis. Endocrinol Metab Clinics NA 29:417, 2000.159. Casey BM, Dashe JS, Wells CE, et al: Clinical hypothyroidism and preg- 183. Pearce EN, Farwell AP, Braverman LE: Thyroiditis [published erratum nancy outcomes. Obstet Gynecol 105:239, 2005. appears in N Engl J Med 349:62, 2003]. N Engl J Med 348:2646, 2003.160. Casey BM: Subclinical hypothyroidism and pregnancy. Obstet Gynecol 184. Stagnaro-Green AS: Postpartum thyroiditis: Prevalence, etiology, and Surv 61:415, 2006. clinical implications. Thyroid Today 16:1, 1993.161. Gharib H, Cobin RH, Dickey RA: Subclinical hypothyroidism during 185. Gerstein HC: Incidence of postpartum thyroid dysfunction in patients pregnancy: Position statement from the American Association of Clinical with type I diabetes mellitus. Ann Intern Med 188:419, 1993. Endocrinologists. Endocr Pract 5:367, 1999. 186. Alvarez-Marfany M, Roman SH, Drexler AJ, et al: Long-term prospective162. Vaidya B, Anthony S, Bilous M, et al: Detection of thyroid dysfunction in study of postpartum thyroid dysfunction in women with insulin depen- early pregnancy: Universal screening or targeted high risk case finding. J dent diabetes mellitus. J Clin Endocrinol 79:10, 1994. Clin Endocrinol Metab 92:203, 2007. 187. Adams H, Jones MC, Othman S, et al: The sonographic appearances in163. Pop VJ, Brouwers EP, Vader HL, et al: Maternal hypothyroxinemia during postpartum thyroiditis. Clin Radiol l45:311, 1992. early pregnancy and subsequent child development: A 3-year follow-up 188. Pedersen CA: Postpartum mood and anxiety disorders: A guide for the study. Clin Endocrinol 59:282, 2003. non-psychiatric clinician with an aside on thyroid associations with post-164. Demers L, Spencer CA: Laboratory medicine practice guidelines: Labora- partum mood. Thyroid 9:691, 1999. tory support for the diagnosis and monitoring of thyroid disease. Thyroid 189. Harris B, Fung H, Johns S, et al: Transient postpartum thyroid dysfunction 13:6,2003. and postnatal depression. J Affect Disord 17:243, 1989.165. Glinoer D, De Nayer P, Bourdoux P, et al: Regulation of maternal thyroid 190. Pop VJM, de Rooy HAM, Vader HL, et al: Postpartum thyroid dysfunction during pregnancy. J Clin Endocrinol Metab 71:276, 1990. and depression in an unselected population. N Engl J Med 324:1815,166. Mandel SJ, Spencer CA, Hollowell JG: Are detection and treatment of 1991. thyroid insufficiency in pregnancy feasible? Thyroid 15:44, 2005. 191. Harris B, Othman S, Davies JA, et al: Association between postpartum167. Morreale de Escobar G, Obregon MJ, Escobar del Rey F: Is neuropsycho- thyroid dysfunction and thyroid antibodies and depression. BMJ 305:152, logical development related to maternal hypothyroidism or to maternal 1992. hypothyroxinemia? J Clin Endocrinol Metab 85:3975, 2000. 192. Pop VJM, de Rooy HAM, Vader VL, et al: Microsomal antibodies during168. Larsen PR: Detecting and treating hypothyroidism during pregnancy. Nat gestation in relation to postpartum thyroid dysfunction and depression. Clin Pract Endocrinol Metab 2:59, 2006. Acta Endocrinol 129:26, 1993.169. Dussault JH, Rousseau F: Immunologically mediated hypothyroidism. 193. Pop VJM, Maarteens LH, Levsink G, et al: Are autoimmune thyroid dys- Endocrinol Metab Clin North Am 16:417, 1987. function and depression related? J Clin Endocrinol Metab 83:3194,170. Bogner U, Gruters A, Sigle B, et al: Cytotoxic antibodies in congenital 1998. hypothyroidism. J Clin Endocrinol Metab 68:671, 1989. 194. Tachi J, Amino N, Tamaski H, et al: Long-term follow-up and HLA asso-171. Gruner C, Kollert A, Wildt L, et al: Intrauterine treatment of fetal goitrous ciation in patients with postpartum hypothyroidism. J Clin Endocrinol hypothyroidism controlled by determination of thyroid-stimulating Metab 66:480, 1988. hormone in fetal serum. A case report and review of the literature. Fetal 195. Othman S, Phillips DL, Parkes AB, et al: Long-term follow-up of postpar- Diagn Ther 16:47, 2001. tum thyroiditis. Clin Endocrinol 32:559, 1990.172. Kung A, Chau M, Lao T, et al: The effect of pregnancy on thyroid nodule 196. Stagnaro-Green AS: Post-miscarriage thyroid dysfunction. Obstet Gynecol formation. J Clin Endocrinol Metab 87:1010, 2002. 803:490, 1992.173. Hay ID: Nodular thyroid disease diagnosed during pregnancy: How and 197. Marqusee E, Hill JA, Mandel SJ: Thyroiditis after pregnancy loss. J Clin when to treat. Thyroid 9:667, 1999. Endocrinol Metab 82:2455, 1997.174. Tan GH, Gharib H, Goellner JR, et al: Management of thyroid nodules in 198. Kampe O, Jansson R, Karlsson FA: Effects of L-thyroxine and iodide on pregnancy. Arch Intern Med 156:2317, 1996. the development of autoimmune postpartum thyroiditis. J Clin Endocri-175. Marley EF, Oertil YC: Fine needle aspiration of thyroid lesions in 57 nol Metab 70:1014, 1990. pregnant and postpartum women. Diagn Cytopathol 16:122, 1997. 199. Weetman AP: Editorial: Insulin-dependent diabetes mellitus and postpar-176. Moosa M, Mazzaferri EL: Outcome of differentiated thyroid cancer diag- tum thyroiditis: An important association. J Clin Endocrinol Metab 79:7, nosed in pregnant women. J Clin Endocrinol Metab 82:2862, 1997. 1994.177. Herzon FS, Morris DM, Segal MN, et al: Coexistent thyroid cancer and pregnancy. Arch Otolaryngol Head Neck Surg 120:1191, 1994.